

External Quality Review FINAL Annual Technical Report AmeriHealth Caritas Louisiana

Louisiana Department of Health
State Fiscal Year 2021

Review Period: July 1, 2020-June 30, 2021

Table of Contents

I.	EXECUTIVE SUMMARY	I-5
F	Purpose of Report	I-5
9	Scope of External Quality Review Activities Conducted	I-5
ŀ	HIGH-LEVEL PROGRAM FINDINGS AND RECOMMENDATIONS	I-6
	CONCLUSION	
F	RECOMMENDATIONS FOR LDH	I-9
F	RECOMMENDATIONS FOR MCO	I-9
II.	LOUISIANA MEDICAID MANAGED CARE PROGRAM	II-10
	Managed Care in Louisiana	
	LOUISIANA MEDICAID QUALITY STRATEGY	
	IPRO'S ASSESSMENT OF THE LOUISIANA MEDICAID QUALITY STRATEGY	
	Strengths	
	OPPORTUNITIES FOR IMPROVEMENT	
	RECOMMENDATIONS	
	HEALTH DISPARITIES QUESTIONNAIRE	
	VALIDATION OF PERFORMANCE IMPROVEMENT PROJECTS	
	Objectives	
	TECHNICAL METHODS OF DATA COLLECTION AND ANALYSIS	
	DESCRIPTION OF DATA OBTAINED	
(Conclusions	III-18
IV.	REVIEW OF COMPLIANCE WITH MEDICAID AND CHIP MANAGED CARE REGULATIONS	IV-28
(Objectives	IV-28
	TECHNICAL METHODS OF DATA COLLECTION AND ANALYSIS	
	DESCRIPTION OF DATA OBTAINED	
	CONCLUSIONS	
F	FINDINGS BY DOMAIN	IV-30
٧.	VALIDATION OF PERFORMANCE MEASURES	V-31
(Objectives	V-31
٦	TECHNICAL METHODS OF DATA COLLECTION AND ANALYSIS	V-31
[DESCRIPTION OF DATA OBTAINED	V-32
(Conclusions	
VI.		
(Objectives	VI-36
	TECHNICAL METHODS OF DATA COLLECTION AND ANALYSIS	
[DESCRIPTION OF DATA OBTAINED	VI-36
(Conclusions	VI-36
VII.	VALIDATION OF NETWORK ADEQUACY	VII-40
(GENERAL NETWORK ACCESS REQUIREMENTS	VII-40
(GeoAccess Provider Network Accessibility	VII-40
٦	TECHNICAL METHODS OF DATA COLLECTION AND ANALYSIS	VII-40
[DESCRIPTION OF DATA OBTAINED	VII-41
(Conclusions	VII-41
	Provider Appointment Availability	
	TECHNICAL METHODS OF DATA COLLECTION AND ANALYSIS	
	DESCRIPTION OF DATA OBTAINED	
	Conclusions	
F	RECOMMENDATION	VII-44
VIII	I. MCO QUALITY RATINGS	VIII-45

Objectives	VIII-45
OBJECTIVES TECHNICAL METHODS OF DATA COLLECTION AND ANALYSIS DESCRIPTION OF DATA OBTAINED	VIII-45
DESCRIPTION OF DATA OBTAINED	VIII-46
Conclusions	VIII-46
IX. EQRO'S ASSESSMENT OF MCO RESPONSES TO THE PREVIOUS EQR RECOMMENDATIONS	IX-49
ACLA RESPONSE TO PREVIOUS EQR RECOMMENDATIONS	IX-49
X. MCO STRENGTHS, OPPORTUNITIES FOR IMPROVEMENT, AND EQR RECOMMENDATIONS	X-54
ACLA STRENGTHS AND OPPORTUNITIES FOR IMPROVEMENT, AND EQR RECOMMENDATIONS	X-54
XI. APPENDIX A	XI-58
MCO VERBATIM RESPONSES TO IPRO'S HEALTH DISPARITIES QUESTIONNAIRE	XI-58
ACLA RESPONSE	XI-58
XII. APPENDIX B	XII-61
IPRO'S ASSESSMENT OF THE LOUISIANA MEDICAID QUALITY STRATEGY	
Evaluation Methodology	XII-61

List of Tables

TABLE 1: LIST OF CURRENT LOUISIANA MEDICAID MCOS BY ENROLLMENT	II-10
TABLE 2: MCO PIP TOPICS	III-16
TABLE 3: PIP VALIDATION REVIEW DETERMINATIONS	III-17
TABLE 4: PIP VALIDATION RESULTS FOR PIP ELEMENTS — ACLA	III-18
Table 5: ACLA PIP Summaries, 2020–2021	III-22
Table 6: Assessment of AHCLA PIP Indicator Performance – Measurement Year 2 (2020)	III-26
Table 7: Review Determination Definitions	
TABLE 8: CFR STANDARDS TO STATE CONTRACT CROSSWALK	IV-30
Table 9: ACLA Compliance with Information System Standards – MY 2020	V-32
TABLE 10: ACLA HEDIS EFFECTIVENESS OF CARE MEASURES – MY 2020	V-32
Table 11: ACLA HEDIS Access to/Availability of Care Measures – MY 2020	V-34
TABLE 12: ACLA HEDIS USE OF SERVICES MEASURES – MY 2020	V-34
TABLE 13: ACLA HEDIS MEASURES SUMMARY – MY 2020	V-35
Table 14: CAHPS Performance – Adult Member	•••••••••••••••••••••••••••••••••••••••
Table 15: CAHPS Performance – Child Member (without chronic conditions)	VI-37
Table 16: CAHPS Performance – Child Member with Chronic Condition(s)	VI-38
TABLE 17: ACLA ADULT CAHPS 5.0H – 2018–2021 AND NATIONAL BENCHMARK MET/EXCEEDED IN 2021	VI-38
TABLE 18: ACLA CHILD CAHPS 5.0H GENERAL POPULATION – 2018–2021	
TABLE 19: ACLA CHILD CAHPS 5.0H CCC POPULATION – 2018–2021	VI-39
Table 20: Louisiana Network Access Standards	VII-40
TABLE 21: ACLA ADULT PCP-TO-MEMBER RATIOS, MY 2018–MY 2020	VII-41
TABLE 22: ACLA PEDIATRIC PCP-TO-MEMBER RATIOS, MY 2018–MY 2020	
TABLE 23: ACLA ADHERENCE TO PROVIDER NETWORK DISTANCE STANDARDS, JUNE 2021	VII-41
TABLE 24: APPOINTMENT AVAILABILITY FOR NETWORK PROVIDERS, FIRST HALF OF 2021	VII-44
TABLE 25: MCO RESPONSE TO RECOMMENDATION ASSESSMENT LEVELS	IX-49
TABLE 26: ACLA RESPONSE TO PREVIOUS EQR RECOMMENDATIONS	IX-49
TABLE 27: ACLA STRENGTHS AND OPPORTUNITIES FOR IMPROVEMENT, AND EQR RECOMMENDATIONS	X-54
List of Figures	

FIGURE 1: MCO QUALITY REPORT CA	ARD\	/III-47

Healthcare Effectiveness Data and Information Set (HEDIS®) and Quality Compass® are registered trademarks of the National Committee for Quality Assurance (NCQA). Consumer Assessment of Healthcare Providers and Systems (CAHPS®) is a registered trademark of the Agency for Healthcare Research and Quality (AHRQ). Triple Aim® is a registered trademark of the Institute for Healthcare Improvement (IHI). Current Procedural Terminology (CPT®) is a registered trademark of the American Medical Association.

I. Executive Summary

Purpose of Report

The Balanced Budget Act (BBA) of 1997 established that state agencies contracting with managed care organizations (MCOs) provide for an annual external, independent review of the quality outcomes, timeliness of and access to the services included in the contract between the state agency and the MCO. *Title 42 Code of Federal Regulations (CFR) Section (§) 438.350 External quality review (a)* through (f) sets forth the requirements for the annual external quality review (EQR) of contracted MCOs. States are required to contract with an external quality review organization (EQRO) to perform an annual EQR for each contracted MCO. The states must further ensure that the EQRO has sufficient information to carry out this review, that the information be obtained from EQR-related activities and that the information provided to the EQRO be obtained through methods consistent with the protocols established by the Centers for Medicare and Medicaid Services (CMS). Quality, as it pertains to an EQR, is defined in 42 CFR § 438.320 Definitions as "the degree to which an MCO, PIHP¹, PAHP², or PCCM³ entity increases the likelihood of desired health outcomes of its enrollees through: (1) its structural and operational characteristics. (2) The provision of health services that are consistent with current professional, evidence-based knowledge. (3) Interventions for performance improvement."

Title 42 CFR § 438.364 External review results (a) through (d) requires that the annual EQR be summarized in a detailed technical report that aggregates, analyzes and evaluates information on the quality of, timeliness of and access to health care services that MCOs furnish to Medicaid recipients. The report must also contain an assessment of the strengths and weaknesses of the MCOs regarding health care quality, timeliness, and access, as well as make recommendations for improvement.

To comply with 42 CFR § 438.364 External review results (a) through (d) and 42 CFR § 438.358 Activities related to external quality review, the Louisiana Department of Health (LDH) contracted with IPRO, an EQRO, to conduct the sate fiscal year (SFY) 2021 EQR activities for five (5) MCOs contracted to furnish Medicaid services in the state. During the period under review, SFY 2021 (July 1, 2020–June 30, 2021), LDH's MCOs included Aetna Better Health of Louisiana (ABHLA), AmeriHealth Caritas Louisiana (ACLA), Healthy Blue of Louisiana (HBL), Louisiana Healthcare Connections (LHCC), and UnitedHealthcare Community Plan of Louisiana (UHC). This report presents aggregate and MCO-level results of the EQR activities for those five health plans.

Scope of External Quality Review Activities Conducted

This EQR technical report focuses on the four (4) mandatory and two (2) optional EQR activities that were conducted. It should be noted that validation of network adequacy and assistance with the quality rating of MCOs were conducted at the state's discretion as activity protocols were not included in the CMS External Quality Review (EQR) Protocols published in October 2019. These updated protocols did state that an "Information Systems Capabilities Assessment (ISCA) is a mandatory component of the EQR as part of Protocols 1, 2, 3, and 4." As set forth in 42 CFR § 438.358 Activities related to external quality review (b)(1), these activities are:

(i) **CMS Mandatory Protocol 1: Validation of Performance Improvement Projects (PIPs)** – This activity validates that MCO performance improvement projects (PIPs) were designed, conducted, and reported in a methodologically sound manner, allowing for real improvements in care and services.

¹ prepaid inpatient health plan.

² prepaid ambulatory health plan.

³ primary care case management.

- (ii) CMS Mandatory Protocol 2: Validation⁴ of Performance Measures This activity assesses the accuracy of performance measures reported by each MCO and determined the extent to which the rates calculated by the MCO follow state specifications and reporting requirements.
- (iii) CMS Mandatory Protocol 3: Review of Compliance with Medicaid and CHIP Managed Care
 Regulations This activity determines MCO compliance with its contract and with state and federal regulations.
- (iv) **CMS Mandatory Protocol 4:** Validation of Network Adequacy This activity assesses MCO adherence to state standards for distance for specific provider types, as well as the MCO's ability to provide an adequate provider network to its Medicaid population. (CMS has not published an official protocol for this activity.)
- (v) **CMS Optional Protocol 6:** Administration or Validation of Quality of Care Surveys In SFY 2021, the CAHPS satisfaction survey was conducted, one for adult and child members.
- (vi) CMS Optional Protocol 10: Assist with the Quality Rating of Medicaid and CHIP MCOs This activity summarizes MCO performance in a manner that allows beneficiaries to easily make comparisons and to identify strengths and weakness in high priority areas. (CMS has not published an official protocol for this activity.)

While the CMS External Quality Review (EQR) Protocols published in October 2019 stated that an ISCA is a required component of the mandatory EQR activities, CMS later clarified that the systems reviews that are conducted as part of the National Committee for Quality Assurance (NCQA) Healthcare Effectiveness Data and Information Set (HEDIS®) Compliance Audit™ may be substituted for an ISCA. Findings from IPRO's review of the MCOs' HEDIS final audit reports (FARs) are in the **Validation of Performance Measures** section of this report.

The results of these EQR activities are presented in individual activity sections of this report. Each of the activity sections includes information on:

- data collection and analysis methodologies,
- comparative findings, and
- where applicable, the MCOs' performance strengths and opportunities for improvement.

High-Level Program Findings and Recommendations

IPRO used the analyses and evaluations of 2020–2021 EQR activity findings to assess the performance of Louisiana Medicaid MCOs in providing quality, timely, and accessible healthcare services to Medicaid members. The individual Managed Care Organizations (MCOs) were evaluated against state and national benchmarks for measures related to the quality, access, and timeliness domains, and results were compared to previous years for trending when possible.

The following provides a high-level summary of these findings for the Louisiana Medicaid Managed Care Program. The overall findings for MCOs were also compared and analyzed to develop overarching conclusions and recommendations for each MCO. These plan-level findings are discussed in each EQR activity section as well as the **Conclusion** section.

Of note, MY 2020 performance coincides with the peak of the COVID-19 pandemic. The impact of the COVID-19 pandemic should be considered when evaluating statewide and MCP performance trends presented in this report.

⁴ CMS defines *validation* in *42 CFR § 438.320 Definitions* as "the review of information, data, and procedures to determine the extent to which they are accurate, reliable, free from bias, and in accord with standards for data collection and analysis."

Strengths Related to Quality, Timeliness and Access

Performance Improvement Projects

Full validation results for 2020 PIPs and partial results for the 2021 PIPs are described in **Section III** of this report.

Four PIPs were conducted by each MCO during the ATR review period. Two PIPs (2020) have been completed:

- 1. Improving Rates for (1) Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence

 Treatment (IET) and (2) Follow-Up After Emergency Department Visit for Alcohol and Other Drug Abuse or

 Dependence
- **Strength:** Two performance indicators showed improvement from baseline to final remeasurement of at least 3 percentage points⁵.
- 2. Improve Screening for Chronic Hepatitis C Virus (HCV) and Pharmaceutical Treatment Initiation
 - **Strength:** Six performance indicators demonstrated improvement of at least 3 percentage points from baseline to final remeasurement⁶.

Two additional PIPs (2021) are currently being conducted by the MCOs, and are not completed:

- 3. Ensuring access to the COVID-19 vaccine among Healthy Louisiana vaccine-eligible enrollees: Persons 18 years of age or older
 - **Strength:** While it is still too early to assess the overall results of this PIP, there were no validation findings that indicate that the credibility of the PIP results is at risk.
- 4. Improving Receipt of Global Developmental Screening in the First Three Years of Life
 - **Strength:** While it is still too early to assess the overall results of this PIP, there were no validation findings that indicate that the credibility of the PIP results is at risk.

Review of Compliance with Medicaid and CHIP Managed Care Regulations

ACLA achieved a "full" compliance review in the following domains: Availability of Services, Coordination and Continuity of Care, Coverage and Authorization of Services, Provider Selection, Confidentiality, Grievance and Appeal Systems, Subcontractual Relationships and Delegation, Practice Guidelines, Health Information Systems, and Quality Assurance and Performance Improvement (QAPI). There were no review domains in which ACLA received a review determination of "minimal" or "not met". A complete summary of ACLA's compliance results for Medicaid and CHIP Managed Care regulations can be found within **Section IV**.

Validation of Performance Measures

IPRO's validation of ACLA's performance measures confirmed the state's compliance with the standards of 42 CFR § 438.330(a)(1). The results of the validation activity determined that ACLA was compliant with the standards of 42 CFR § 438.330(c)(2).

Information Systems Capabilities Assessment

Based on a review of the FARs issued by ACLA's independent auditor, IPRO found that ACLA was determined to be fully compliant with all seven of the applicable NCQA HEDIS IS standards.

⁵ The final interim rates reported extend past the ATR review period (July 1, 2019 – June 30, 2020). This allows for sufficient data to be reported to draw conclusions about the PIP.

⁶ The final interim rates reported extend past the ATR review period (July 1, 2019 – June 30, 2020). This allows for sufficient data to be reported to draw conclusions about the PIP.

NCQA MY 2020 National Medicaid Benchmarks using National - All LOBs (Excluding PPOs and EPOs) are referenced in this section, unless stated otherwise.

HEDIS – Quality, Timeliness and Access

Of the 66 HEDIS measures/submeasures reported by ACLA, 30 (45%) of the measures performed equal to or greater than the NCQA 50th percentile benchmark. Among the incentive measures, ACLA achieved rates above the NCQA 50th percentile benchmark in 6 measures.

Quality of Care Surveys

Member Satisfaction

ACLA's adult member Consumer Assessment of Healthcare Providers and Systems (CAHPS) scores met or exceeded the national Medicaid benchmarks presented in the NCQA *Quality Compass®* for the following measures: Getting Needed Care, How Well Doctors Communicate, and Rating of Health Plan. Of note, the Customer Service and Rating of All Health Care satisfaction scores for adult members fell within the 75th percentile.

For child members without chronic condition(s), ACLA ranked between the 50th and 75th percentile for three measures: How Well Doctors Communicate, Customer Service, and Rating of Specialist Seen Most Often. ACLA was at or above the 75th percentile for the following measures: Getting Needed Care, Getting Care Quickly, Rating of All Health Care, and Rating of Personal Doctor. Small sample sizes were identified for ACLA's Customer Service and Rating of Specialist Seen Most Often measures.

For child members with chronic condition(s), ACLA was between the 50th and 75th percentile for Getting Needed Care, Rating of All Health Care, and Rating of Health Plan. ACLA was at or above the 75th percentile for four (4) measures: Getting Care Quickly, Customer Service, Rating of Personal Doctor, and Rating of Specialist Seen Most Often. Small sample sizes were identified for ACLA's Customer Service, and Rating of Specialist Seen Most Often measures.

Statewide averages and ACLA-specific CAHPS results for all adult and child members can be found within **Section VI**.

Network Adequacy

None Identified.

Quality Ratings

ACLA scored high in the categories of overall consumer experience, satisfaction with plan physicians and satisfaction with plan physicians (four stars).

Opportunities Related to Quality, Timeliness and Access

Performance Improvement Projects

ACLA demonstrated opportunities to improve on six indicators in the <u>Improving Rates for IET of AOD Abuse or Dependence and Follow-Up After Emergency Department Visit for AOD Abuse or Dependence PIP and five indicators in the <u>Improve Screening for HCV and Treatment Initiation</u> PIP. A summary of all performance indicators is shown in **Section III**.</u>

Review of Compliance with Medicaid and CHIP Managed Care Regulations

ACLA received less than a "full" review determination in the domain of Assurances of Adequate Capacity and Services. A complete summary of ACLA compliance results for Medicaid and CHIP Managed Care regulations can be found within **Section IV**.

Performance Measures

HEDIS – Quality, Access, and Timeliness

In MY 2020, ACLA had 4 of 66 HEDIS measures lower than the 10th NCQA national benchmark, and 12 of 66 HEDIS measures between the 10th and 25th NCQA national benchmark.

Quality of Care Surveys

Member Satisfaction

ACLA's adult member CAHPS scores ranked below the 50th percentile for the following measures: Getting Care Quickly, Rating of Personal Doctor, and Rating of Specialist Seen Most Often.

ACLA's child members without chronic condition(s) CAHPS score ranked below the 50th percentile for the Rating of Health Plan measure.

ACLA's child members with chronic condition(s) CAHPS score ranked below the 50th percentile for How Well Doctors Communicate.

ACLA-specific CAHPS results for all adult and child members can be found within Section VI.

Network Adequacy

Both the adult and pediatric PCP-to-member ratios declined for ACLA from MY 2018 to MY 2020. With regard to provider network distance standards, ACLA met only 23% of the standards.

Quality Ratings

ACLA scored low in the categories of treatment for asthma, diabetes, mental/behavioral health, as well as overall treatment (two stars).

Conclusion

Findings from SFY 2021 EQR activities highlight ACLA's continued commitment to achieving the goals of the Louisiana Medicaid Quality Strategy. Strengths related to **quality** of care, **timeliness** of care, and **access** to care were observed across all covered populations encompassing physical health. In addition, as achieving health equity remains a state priority, opportunities to improve health disparities continue at ACLA.

Recommendations for LDH

Recommendations towards achieving the goals of the Louisiana Medicaid Quality Strategy are presented in **Section II** of this report.

Recommendations for MCO

MCO-specific recommendations related to the quality of, timeliness of, and access to care are presented in **Section X** of this report.

II. Louisiana Medicaid Managed Care Program

Managed Care in Louisiana

On February 1, 2012, the Louisiana Department of Health (LDH) transitioned approximately 900,000 Medicaid enrollees from the state's fee-for-service (FFS) program to a managed care program. The rollout occurred in phases based on designated geographic service areas, resulting in a completed statewide rollout on June 1, 2012.

In 2014, a request for proposal (RFP) was issued for full-risk Medicaid managed care contracts, with a start date of February 1, 2015. The RFP provided for an initial 3-year contract term and the option to extend the contracts up to 24 months. Subsequently, the Louisiana Legislature approved a 23-month extension to these contracts, from February 1, 2018, through the contract expiration date of December 31, 2019. In December 2015, LDH integrated specialized behavioral health services into the managed care program in an effort to improve care coordination for enrollees and facilitate provision of whole-person health care. Louisiana also continued to administer the Coordinated System of Care (CSoC), a single Behavioral Health PIHP (managed by Magellan of Louisiana CSoC Program) to help children with behavioral health challenges that are at risk for out-of-home placement.

Louisiana Medicaid currently serves over 1.7 million enrollees, approximately 37% of the state's population. There are five statewide MCOs: Aetna Better Health of Louisiana (ABHLA), AmeriHealth Caritas Louisiana (ACLA), Healthy Blue of Louisiana (HBL), Louisiana Healthcare Connections (LHCC), and UnitedHealthcare Community Plan of Louisiana (UHC). In February 2020, the state announced its intent to contract with two dental Prepaid Ambulatory Health Plans (PAHPs) for Medicaid following a state bid process that began in June 2019 when the Department issued a request for proposals. LDH selected DentaQuest USA Insurance Company, Inc. and MCNA Insurance Company d/b/a MCNA Dental Plans as its dental partners, effective January 1, 2021. On June 24, 2021, LDH initiated procurement for its full-risk Medicaid managed care contracts. Responses to this RFP were due by September 3, 2021.

Healthy Louisiana covers more than 90% of Louisiana Medicaid members, including more than 800,000 new members since Medicaid expansion took effect in July 2016. In addition to providing benefits as specified in the Medicaid State Plan, state statutes, administrative rules, and Medicaid policy and procedure manuals, these MCOs also provide case management services and certain value-added Medicaid benefits. Healthy Louisiana statewide enrollment increased by 23.3% from 1,406,048 in June 2020 to 1,733,148 in June 2021. MCO enrollment as of June 2021 ranged from a high of 523,653 for LHCC to 146,484 for ABHLA. Enrollment by current Louisiana Medicaid MCOs is shown in **Table 1**.

Table 1: List of Current Louisiana Medicaid MCOs by Enrollment

	MCO	Enrollment	Enrollment
MCO Name	Acronym	June 2020	June 2021
Aetna Better Health of Louisiana	ABHLA	129,527	146,484
AmeriHealth Caritas Louisiana	ACLA	208,885	223,633
Healthy Blue	HBL	294,513	341,087
Louisiana Healthcare Connections	LHCC	473,872	523,653
UnitedHealthcare Community Plan of Louisiana	UHC	454,397	498,291
Total		1,406,048	1,733,148

Source: Louisiana Department of Health, Report No. 109-A: 1. This report shows all active members in Healthy Louisiana as of July 6, 2021. Members to be dis-enrolled at the end of the reporting month were not included. Enrollees who gained and lost eligibility during the reporting month were not included. Enrollees who opted out of Healthy Louisiana during the reporting month were not included. 2. The statewide total includes membership of all MCOs.

Louisiana Medicaid Quality Strategy

Louisiana's Quality Strategy is based on aims, goals, and objectives to promote improvement in health care delivery and outcomes, along with metrics by which progress can be measured. Louisiana's Quality Strategy is aligned with the Institute of Healthcare Improvement (IHI)'s Triple Aim® and the aims and priorities selected by CMS for their national quality strategy. Posted on the LDH website, Louisiana's 2019 Quality Strategy identifies the following three aims:

- Better Care: Make health care more person-centered, coordinated, and accessible.
- **Healthier People, Healthier Communities**: Improve the health of Louisianans through better prevention and treatment and proven interventions that address physical, behavioral, and social needs; and
- **Smarter Spending:** Demonstrate good stewardship of public resources by ensuring high-value, efficient care.

Within LDH, the Bureau of Health Services Financing (BHSF) is responsible for the day-to-day operations of the MMC program, with support from other LDH program offices, including the Office of Behavioral Health (OBH), Office of Public Health (OPH), Office of Aging and Adult Services (OAAS), and the Office for Citizens with Developmental Disabilities (OCDD). The Medicaid Quality Improvement and Innovations Section, in collaboration with these program offices, the Medicaid Chief Medical Officer, and the Medicaid Executive Management Team, are responsible for the development, implementation and evaluation of the Medicaid Managed Care Quality Strategy.

The Louisiana Medicaid Medical Care Advisory Committee (formerly known as the Medicaid Quality Committee) provides consultation on quality improvement activities to promote access and utilization of quality, evidence-based healthcare that is designed to meet the health needs of all Louisiana Medicaid and Children's Health Insurance Program enrollees. Members of the Medicaid Medical Care Advisory Committee and its subcommittees fulfill the role required by federal regulation 42 CFR 431.12. This committee is interdisciplinary and includes representatives who are familiar with quality improvement and the medical needs of Healthy Louisiana enrollees.

The Louisiana Department of Health 2021 Quality Strategy is available for viewing on its website.

IPRO's Assessment of the Louisiana Medicaid Quality Strategy

A summary of IPRO's evaluation methodology is described in **Appendix B**.

Strengths

- Aligned with Institute of Healthcare Improvement (IHI)'s Triple Aim and the aims and priorities selected by CMS for their national quality strategy, Louisiana's Quality Strategy established three aims:
 - Better Care: Make healthcare more person-centered, coordinated, and accessible.
 - Healthier People, Healthier Communities: Improve the health of Louisianans through better prevention and treatment and proven interventions that address physical, behavioral, and social needs.
 - o **Smarter Spending:** Demonstrate good stewardship of public resources by ensuring high-value, efficient care.
- LDH requires all 5 Healthy Louisiana MCOs to annually report quality performance measures including
 HEDIS quality metrics, CMS Adult and Children Core Data Sets, AHRQ Prevention Quality Indicators, CAHPS
 consumer satisfaction, and several state-specified quality measures.
 - Louisiana Medicaid MCOs showed a good level of performance for achieving either the national benchmark target or the improvement objective or both for the 16 Incentive-Based measures selected by LDH. Statewide rates for 9 of the 16 incentive-based measures (56%) met either the target objective

- or the improvement objective, or both. Statewide rates for three of the measures met both the national target and the improvement objective.
- Of the 61 non-incentive HEDIS performance measures that could be trended, 40 statewide measure rates (66%) showed improvement between HEDIS 2019 2020; however, only 12 of the measures (20%) improved by at least 2.0 percentage points from the prior year.
- Of the 56 non-incentive HEDIS measures that could be compared to the 2020 NCQA Quality Compass benchmark rates, 15 measures (27%) had rates at or above the national 50th percentile, including 5 measures with rates at or above the national 75th percentile but lower than the 90th percentile.
- For the state-specific measures submitted by the MCOs in 2020, 12 of the 16 statewide measure rates (75%) showed improvement between RYs 2019 and 2020, including five measures where a lower rate indicates better performance. Three of the 16 statewide measure rates met the improvement objective.
- LDH conducted a robust set of monitoring activities tracking enrollment, network adequacy, quality of care, member satisfaction, program transparency, medical loss ratio, claims and diabetes and obesity.
- In compliance with federal regulations, the EQRO prepared federally required MCO Annual Technical Reports. Results for each MCO and a state summary are posted on the LDH website.
- The 2020 annual compliance audit was a partial audit of each of the five MCOs' compliance with federal
 and state contractual requirements during the period of April 1, 2019, through March 31, 2020. Overall
 results indicated a good level of full compliance for HBL, with 87% of total elements reviewed with full
 compliance, followed by ACLA and UHC, each achieving 61% of total elements at full compliance, and
 LHCC, with 58% at full compliance.
- LDH has shown its commitment to ensuring that improvements in health outcomes lead to equitable improvements in all groups as it continues to integrate procedures for identifying, evaluating, and reducing health disparities throughout the Healthy Louisiana program.
- There is effective communication between the state, MCOs, and the EQRO as evidenced by regularly scheduled meetings and conference calls for EQR activities. LDH commendably communicates with the MCOs, enrollees and the public through a well-designed and informative internet website.
- There is a structured and standardized approach in place for conducting and validating PIPs. Louisiana's
 statewide collaborative PIP model offers an opportunity for shared learning and an avenue to address the
 same message to all MMC providers and members. Individual MCO conference calls with the EQRO,
 quarterly update reports and monthly or quarterly Collaborative PIP meetings provide valuable insight on
 PIP progress, and through the use of intervention tracking measures can help quantify opportunities for
 improvement.
- Healthy Louisiana has successfully integrated quality as a fundamental aspect of the managed care
 program by introducing an MCO withhold of capitation payment program to improve health outcomes and
 increase the use of VBP.

Opportunities for Improvement

- Opportunities for improvement are evident for seven statewide incentive-based measures (44%) that failed to meet either the national target or the improvement objective:
 - Ambulatory Care ED Visits/1,000MM;
 - Comprehensive Diabetes Care HbA1c Testing;
 - o Comprehensive Diabetes Care Eye (retinal) Exam Performed;
 - o Follow-up after Hospitalization for Mental Illness Within 30 Days of Discharge;
 - Well-Child Visits in First 15 Months of Life Six or more well-child visits;
 - o Well-Child Visits in the Third, Fourth, Fifth and Sixth Years of Life; and
 - o Initiation of Injectable Progesterone for Preterm Birth Prevention.

- A total of 20 of the 61 non-incentive-Based HEDIS performance measures (33%) did not show improvement in statewide rates between HEDIS 2019 and HEDIS 2020, including the CDC HbA1c Poor Control (> 9.0%) measure where a lower rate indicates better performance. Of the 56 measures in this measure set with national *Quality Compass* benchmarks, opportunities for improvement are evident for 20 measures (36%), with rates below the national 25th percentile.
- Opportunities for improvement should also address the following state-specific performance measures that did not meet either the target objective or the improvement objective:
 - 6 of the 8 Contraceptive Care Postpartum measures;
 - o Percentage of Low Birth Weight Births;
 - Elective Delivery;
 - Diabetes Short-Term Complications Admission Rate;
 - Heart Failure Admission Rate; and
 - o Asthma in Younger Adults Admission Rate.
- The following 2019 Compliance Review findings indicate opportunities for improvement:
 - Of a total of 244 elements reviewed overall, 91 (37%) were not fully compliant including: 41 elements for ABHLA, 16 elements for UHC, 13 elements for LHCC, 12 elements for ACLA, and 9 elements for HBL.
 - For the five MCOs, a total of 60 elements were not fully compliant for the Provider Network Requirement domain. The EQRO suggested that MCOs conduct outreach to recruit providers, especially in key areas such as specialists and subspecialists, as this is a common problem in the Louisiana Medicaid managed care program.

Recommendations

Overall, LDH is successfully implementing the 2019 Quality Strategy, but it is recommended that LDH, in collaboration with the EQRO and the MCOs, address the above listed opportunities for improvement and the following recommendations.

- While the statewide results of the incentivized measures demonstrated success in terms of the number of measures resulting in withhold payments returned to the MCOs, each of the MCOs has a different set of measures that present opportunities for their improvement. There were 3 Incentive-Based measures where all five MCOs met either the achievement target, or the improvement objective, or both, while there were 13 measures that had at least one MCO not meeting either objective. Each MCO needs to examine their own results to determine how best to target interventions for improvement.
- For the non-incentive HEDIS performance measures and the state-specific measures, LDH should examine each of the measures that have statewide average rates that are not improving over time or that are below the desired benchmarks. To prioritize where improvement is most needed, LDH could start with the 20 HEDIS measure rates that were below the Medicaid *Quality Compass* 25th percentile for HEDIS 2020. Further analysis by MCO may indicate whether poor performance is mainly a problem with one or two MCOs, or if it is an issue for most MCOs. Conducting barrier analysis on these prioritized areas may suggest the need to implement interventions such as future PIPs or focused clinical studies.
- 2020 Compliance audit results and the PCP Access and Availability Survey results continue to indicate a need to further address provider network adequacy, which was identified in both reports as a common problem. LDH may want to consider methods of supporting the MCOs in their outreach to recruit providers, especially in key areas such as specialists and subspecialists in urban areas. This problem area and how it will be addressed should be a focus in the upcoming review of MCO applications in response to the recent procurement for Louisiana Medicaid managed care. It should also be noted that Network Adequacy Validation is now a mandatory EQR activity, but CMS has not yet published a protocol to support the activity. Once the protocol is created, states will have one year to begin implementation. In anticipation of this requirement, LDH could consider initiating validation activities such as regular provider directory and web-based directory validations and/or provider and member focus groups to better

- understand the barriers both providers and members face in providing and/or accessing medical services through Louisiana's Medicaid managed care system.
- Louisiana's 2019 Medicaid Managed Care Quality Strategy includes a thorough set of HEDIS, CAHPS and state-specific measures to assess quality performance, along with well-considered targets for achievement and improvement. These measures, however, are not specifically aligned with the strategy goals and objectives. An appropriate alignment of measures with goals and objectives would allow LDH to better evaluate their level of success in achieving the stated goals and is recommended that this be included in the state's next updated Quality Strategy.

Health Disparities Questionnaire

For this year's technical report, the LA EQRO evaluated MCOs with respect to their activities to identify and/or address gaps in health outcomes and/or health care among their Medicaid population according to at-risk characteristics such as race, ethnicity, gender, and geography. MCOs were asked to respond to the following questions for the period July 1, 2020–June 30, 2021:

Did the MCO conduct any studies, initiatives, or interventions to identify and/or reduce differences in health outcomes, health status, or quality of care between the MCO's Medicaid population and other types of health care consumers (e.g., commercial members) or between members in Medicaid subgroups (e.g., race, ethnicity, gender, age, socio-economic status, geography, education)?

A summary of ACLA's response is presented below. The full verbatim response is displayed in **Appendix A**.

Summary of ACLA Response

AmeriHealth Caritas Louisiana reviews member responses from the CAHPS survey and HEDIS outcomes to identify opportunities for improvement among groups. CAHPS and HEDIS results are stratified by geography (urban/rural), race, ethnicity and language for comparison. Initiatives include provider engagement/education, and programs targeted towards Hispanic and black enrollees, as well as maternal care and well child visits.

III. Validation of Performance Improvement Projects

Objectives

Title 42 CFR § 438.330(d) establishes that state agencies require contracted MCOs to conduct PIPs that focus on both clinical and non-clinical areas. According to the CMS, the purpose of a PIP is to assess and improve the processes and outcomes of health care provided by an MCO. LDH requires MCOs to conduct PIPs, as set forth by 42 CFR § 438.330(d). LDH contracted with IPRO to conduct the annual validation of PIPs.

Section 14.2.8.2 of the state contract requires the MCO to perform two (2) LDH-approved PIPs for the term of the contract. LDH may require up to two (2) additional projects for a maximum of four (4) projects. The MCO shall perform a minimum of one (1) additional LDH-approved behavioral-health PIP each contract year.

Performance improvement projects shall be designed to achieve, through ongoing measurements and intervention, significant improvement sustained over time, with favorable effects on health outcomes and enrollee satisfaction. Each project must involve the following:

- Measurement of performance using objective quality indicators;
- Implementation of interventions to achieve improvement in the access to and
- Quality of care;
- Evaluation of the effectiveness of the interventions; and
- Planning and initiation of activities for increasing or sustaining improvement.

PIPs engage MCO care and quality managers, providers, and members as a team with the common goal of improving patient care. The MCO begins the PIP process by targeting improvement in annual baseline performance indicator rates and identifying drivers of improved evidence-based performance. The next step is to identify barriers to quality of care and to use barrier analysis findings to inform interventions designed to overcome the barriers to care. Interventions are implemented and monitored on an ongoing basis using quarterly and/or monthly intervention tracking measures (ITMs). Declining or stagnating ITM rates signal the need to modify interventions and re-chart the PIP course. Positive ITM trends are an indication of robust interventions.

The PIP validation procedure builds on the CMS PIP Validation Protocol by evaluating quantitative and qualitative data regarding each of the following PIP components:

- 1. Topic/Rationale
 - a. Impacts the maximum proportion of members that is feasible;
 - b. Potential for meaningful impact on member health, functional status, or satisfaction;
 - c. Reflects high-volume or high-risk conditions; and
 - d. Supported with MCO member data (baseline rates; e.g., disease prevalence).
- 2. Aim
 - a. Specifies performance indicators for improvement with corresponding goals;
 - b. Goal sets a target improvement rate that is bold, feasible, and based upon baseline data and strength of interventions, with rationale (e.g., benchmark); and
 - c. Objectives align aim and goals with interventions.
- 3. Methodology
 - a. Annual performance measures indicated;
 - b. Specifies numerator and denominator criteria;
 - c. Procedures indicate data source, hybrid versus administrative, reliability; and
 - d. Sampling method explained for each hybrid measure.
- 4. Barrier analysis, using one or more of the following:

- a. Susceptible subpopulations identified using claims data on PMs stratified by demographic and clinical characteristics;
- b. Obtain direct member input from focus groups, quality meetings, surveys, and/or care management outreach;
- c. Obtain direct provider input from focus groups, quality meetings, surveys, and/or care management outreach; and
- d. Quality improvement (QI) process data (e.g., fishbone diagram, process flow diagrams).
- 5. Robust interventions that are measurable using ITMs
 - a. Informed by barrier analysis;
 - b. Actions that target member, provider, and MCO;
 - c. New or enhanced, starting after baseline year; and
 - d. With corresponding monthly or quarterly ITMs to monitor progress of interventions.
- 6. Results table
 - a. Performance Indicator rates, numerators, and denominators; and
 - b. Target rate.
- 7. Discussion
 - a. Interpretation of extent to which PIP is successful (e.g., compare final to baseline rates, compare final to target rates, interpret ITM rate trends in support of performance indicator improvement).
- 8. Next steps
 - a. Lessons learned;
 - b. System-level changes made and/or planned; and
 - c. Next steps for each intervention.

Table 2 displays the specific MCO PIP topics that were active during the ATR review period (July 1, 2020 - June 30, 2021).

Table 2: MCO PIP Topics

PIP	PIP Topic	
1	Improving Rates for (1) Initiation and Engagement of Alcohol and Other Drug (AOD) Abuse or Dependence	
	Treatment (IET), (2) Follow-Up After Emergency Department Visit for AOD Abuse or Dependence (FUA), and (3)	
	Pharmacotherapy for Opioid Use Disorder (POD)	
2	Improve Screening for Chronic Hepatitis C Virus (HCV) and Pharmaceutical Treatment Initiation	
3	Ensuring access to the COVID-19 vaccine among Healthy Louisiana vaccine-eligible enrollees: Persons 18 years	
	of age or older	
4	Improving Receipt of Global Developmental Screening in the First Three Years of Life	

MCO: managed care organization; PIP: performance improvement project; COVID-19: 2019 novel coronavirus.

Technical Methods of Data Collection and Analysis

IPRO collects performance indicator data and ITM data reported by the plans in annual PIP reports, quarterly PIP reports, and monthly plan-do-study-act (PDSA) run chart presentations.

IPRO's validation process begins at the PIP proposal phase and continues through the life of the PIP. During the conduct of the PIPs, IPRO provides technical assistance to each MCO. The technical assistance includes feedback.

The baseline measurement period of **PIP 1** was January 1, 2018, to December 31, 2018, with interventions initiated January 1, 2019. The PIP continued into 2021 and the final PIP report was submitted December 31, 2021. The baseline measurement period of **PIP 2** was January 1, 2019, to December 31, 2019, with interventions initiated February 1, 2020.

PIP 3 was started on April 9, 2021 and utilized a baseline measurement from the *COVID-19 Vaccine Report* from December 15, 2020, to March 3, 2021. PIP Interventions were initiated on April 9, 2021. **PIP 4** was started in January 2021 and utilized a baseline measurement from January 1, 2020, to December 31, 2020. PIP Interventions were initiated on February 1, 2021.

CMS's Protocol 1. Validation of Performance Improvement Projects was used as the framework to assess the quality of each PIP, as well as to score the compliance of each PIP with both federal and state requirements. IPRO's assessment involves the following 10 elements:

- 1. Review of the selected study topic(s) for relevance of focus and for relevance to the MCO's enrollment.
- 2. Review of the study question(s) for clarity of statement.
- 3. Review of the identified study population to ensure it is representative of the MCO's enrollment and generalizable to the MCO's total population.
- 4. Review of selected study indicator(s), which should be objective, clear, unambiguous, and meaningful to the focus of the PIP.
- 5. Review of sampling methods (if sampling used) for validity and proper technique.
- 6. Review of the data collection procedures to ensure complete and accurate data were collected.
- 7. Review of the data analysis and interpretation of study results.
- 8. Assessment of the improvement strategies for appropriateness.
- 9. Assessment of the likelihood that reported improvement is "real" improvement.
- 10. Assessment of whether the MCO achieved sustained improvement.

Following the review of the listed elements, the review findings are considered to determine whether the PIP outcomes should be accepted as valid and reliable. Each evaluation element was scored as Met, Partially Met, Not Met, or Not Applicable, based on the information provided by MCO. The criteria for each score are presented in **Table 3**.

Table 3: PIP Validation Review Determinations

Determination	Criteria Description	
Met	ne MCO has demonstrated that it fully addressed the requirement.	
Partially Met	The MCO has demonstrated that it fully addressed the requirement, however not in its entirety.	
Not Met	The MCO has not addressed the requirement.	
Not Applicable	The requirement was not applicable for review.	

PIP: performance improvement project; MCO: managed care organization.

IPRO provided PIP report templates to ACLA for the submission of project proposals, interim updates, and results. All data needed to conduct the validation were obtained through these report submissions.

Upon final reporting, a determination was made as to the overall credibility of the results of each PIP, with assignment of one of three categories:

- There were no validation findings which indicate that the credibility of the PIP results is at risk.
- The validation findings generally indicate that the credibility of the PIP results is not at risk. Results must be interpreted with some caution. (Concerns are enumerated.)
- There are one or more validation findings that indicate a bias in the PIP results. The concerns that put the conclusion at risk are enumerated.

Description of Data Obtained

Information obtained throughout the reporting period included project rationale, aims and goals, target population, performance indicator descriptions, performance indicator rates (baseline, interim, and final), methods for performance measure calculations, targets, benchmarks, interventions (planned and executed), tracking measures and rates, barriers, limitations, and next steps for continuous quality improvement.

IPRO received copies of ACLA's PIP report. The reports included the project topic and rationale (including baseline and benchmark data), objectives, description of the methodology and interventions, results and major conclusions of the project, and next steps.

Conclusions

The PIPs conducted by ACLA in SFY 2021 were determined by IPRO to be methodologically sound. IPRO's detailed PIP validation findings are summarized in **Table 4**. PIP summaries including aim, interventions, and performance summary are displayed in **Table 5** and **Table 6**.

While it is still too early to assess the overall results of the 2021 PIPs, there were no validation findings that indicate that the credibility of the PIP results is at risk.

IPRO's assessment of indicator performance was based on the following four categories:

- Target met (or exceeded), and performance improvement demonstrated.
- Target not met, but performance improvement demonstrated.
- Target not met, and performance decline demonstrated.
- Unable to evaluate performance at this time.

Table 4 shows the validation results for these PIPs.

Table 4: PIP Validation Results for PIP Elements — ACLA

PIP Validation Element	PIP 1	PIP 2	PIP 3	PIP 4
ACLA	Improving Rates for IET of AOD, FUA, and POD	Improve Screening for Chronic HCV and Pharmaceutical Treatment Initiation	Ensuring access to the COVID-19 vaccine among Healthy Louisiana vaccine-eligible enrollees	Improving Receipt of Global Developmental Screening in the First Three Years of Life
1. Topic/ Rationale				
a. Impacts the maximum proportion of members that is feasible	Met	Met	Met	Met
b. Potential for meaningful impact on member health, functional status or satisfaction	Met	Met	Met	Met
c. Reflects high-volume or high- risk conditions	Met	Met	Met	Met
d. Supported with MCO member data (baseline rates; e.g., disease prevalence)	Met	Met	Met	Met

PIP Validation Element	PIP 1	PIP 2	PIP 3	PIP 4
		Improve Screening	Ensuring access to	Improving Receipt
		for Chronic HCV	the COVID-19	of Global
		and	vaccine among	Developmental
	Improving Rates	Pharmaceutical	Healthy Louisiana	Screening in the
A C. A	for IET of AOD,	Treatment	vaccine-eligible	First Three Years of
ACLA	FUA, and POD	Initiation	enrollees	Life
2. Aim	N/a+	NAct	N/a+	N/o+
a. Specifies Performance	Met	Met	Met	Met
Indicators for improvement				
with corresponding goals	Met	Met	Met	Met
b. Goal sets a target	wet	Met	wet	iviet
improvement rate that is bold, feasible, and based upon				
baseline data and strength of				
interventions, with rationale				
(e.g., benchmark)				
c. Objectives align aim and	Met	Met	Met	Met
goals with interventions	Wicc	IVICC	Wicc	IVICC
3. Methodology				
a. Annual Performance	Met	Met	Met	Met
Measures indicated				
b. Specifies numerator and	Met	Met	Met	Met
denominator criteria				
c. Procedures indicate methods	Met	Met	Met	Met
for data collection and analysis				
d. Sampling method explained	Not Applicable	Not Applicable	Not Applicable	Not Applicable
for each hybrid measure				
4. Barrier Analysis, using one or				
more of following:				
a. Susceptible subpopulations	Met	Partially Met	Met	Met
identified using claims data on				
performance measures				
stratified by demographic and				
clinical characteristics				
b. Member feedback	Partially Met	Met	Met	Met
c. Provider feedback	Partially Met	Met	Met	Met
d. QI Process data ("5 Why's",	Met	Met	Met	Met
fishbone diagram)				
5. Robust Interventions that are				
Measurable using Intervention				
Tracking Measures	Dest'ell Mari	Destinii Mari	D. A I	D. 4 - 1
a. Informed by barrier analysis	Partially Met	Partially Met	Met	Met
b. Actions that target member,	Met	Met	Met	Met
provider and MCO	N/a+	N/a+	N / a +	N/a+
c. New or enhanced, starting	Met	Met	Met	Met
after baseline year	Dartially Mast	Dartially Mat	Dartially Mast	N/o+
d. With corresponding monthly	Partially Met	Partially Met	Partially Met	Met
or quarterly intervention				
tracking (process) measures (i.e., numerator/denominator,				
specified in proposal and				
specified in proposal allu				1

PIP Validation Element	PIP 1	PIP 2	PIP 3	PIP 4
		Improve Screening	Ensuring access to	Improving Receipt
		for Chronic HCV	the COVID-19	of Global
		and	vaccine among	Developmental
	Improving Rates	Pharmaceutical	Healthy Louisiana	Screening in the
4.01.4	for IET of AOD,	Treatment	vaccine-eligible	First Three Years of
ACLA	FUA, and POD	Initiation	enrollees	Life
baseline PIP reports, with				
actual data reported in Interim				
and Final PIP Reports)				
6. Results Table (Completed for				
Baseline, Interim and Final Re-				
Measurement Years)				
a. Table shows Performance	Partially Met	Partially Met	Met	Met
Indicator rates, numerators and				
denominators				
b. Table shows target rates and	Met	Met	Met	Met
rationale (e.g., next highest				
Quality Compass percentile)				
7. Discussion (Final PIP Report)				
a. Interpretation of extent to	Met	Met	Met	Met
which PIP is successful				
8. Next Steps (Final PIP Report)				
a. Lessons Learned	Met	Met	Met	Met
b. System-level changes made	Met	Met	Met	Met
and/or planned				
c. Next steps for each	Partially Met	Met	Met	Met
intervention				

PIP: performance improvement project; ACLA: AmeriHealth Caritas Louisiana; IET: Initiation and Engagement of . . . Treatment; AOD: Alcohol and Other Drug; FUA: Follow-Up After Emergency Department Visit for AOD Abuse or Dependence; POD: Pharmacotherapy for Opioid Use Disorder; HCV: Hepatitis C Virus; COVID-19: 2019 novel coronavirus; MCO: managed care organization; QI: quality improvement.

COVID 19 PIP

Through a review conducted in May 2021, IPRO determined that the following validation elements of the <u>Covid-19 PIP baseline report</u> submitted by ACLA did not achieve full compliance:

2b: Partially Met. The Plan did set a goal of 15 percentage point increase, which is a target rate typically set for PIPs; however, on May 4, 2021, President Biden set a goal for 70% of U.S. adults to have received at least one COVID-19 vaccine dose by July 4, 2021. Therefore, it is recommended that the Plan use this benchmark goal to set the same target rate of 70% by July 4, 2021.

3c: Partially Met. In the section, "Describe how plan will monitor ITMs for ongoing QI", indicate how you will obtain ongoing feedback from members and providers regarding COVID-19 vaccination drivers (what is working) and barriers (what is not working).

4a: Partially Met. Pending recalculation and re-evaluation of disparity performance indicators, positive percentage point differences indicate underperformance for white enrollees. What are the barriers? Vaccine hesitancy? Access? How will interventions be tailored and targeted to address barriers?

4b: Partially Met. Each month, the Plan should obtain direct member feedback to identify barriers and adapt/adopt interventions to address barriers. New barriers can be summarized in Table 4, in the intervention row, beneath each intervention to which the barrier applies. If additional space is needed to elaborate newly identified barriers for each month, footnote each month separately and describe both the barrier and the adapted/adopted intervention to address each barrier in a monthly footnote beneath table 4.

4c: Partially Met. Each month, the Plan should obtain direct provider feedback to identify drivers (what works) and spread successes, as well as barriers (what does not work) and adapt/adopt interventions to address barriers. New barriers can be summarized in Table 4, in the intervention row, beneath each intervention to which the barrier applies. If additional space is needed to elaborate newly identified barriers for each month, footnote each month separately and describe both the barrier and the adapted/adopted intervention to address each barrier in a monthly footnote beneath table 4.

5a: Partially Met. Pending recalculation and re-evaluation of disparity performance indicators, negative percentage point differences indicate underperformance for nonwhite enrollees and positive percentage point differences indicate underperformance for White enrollees. What are the barriers? Vaccine hesitancy? Access? Mistrust? Other? How will interventions be tailored and targeted to address barriers?

5d: Partially Met. Please revise the Rate % provided for ITM 4(bb) to 42.80%

6a: Partially Met. Per the updated PIP template, Disparity Indicators are calculated as follows: % black individuals minus % white individuals; % Hispanic/Latino individuals minus % white individuals; and % of Other/Unknown individuals minus % white individuals. There should be no numerators or denominators reported.

6b: Partially Met. The target percentage point difference for disparity indicators should be zero percent difference, or as close as possible, as you want to reduce disparities. The Plan did set a goal of 15 percentage point increase, which is a target rate typically set for PIPs; however, on May 4, 2021, President Biden set a goal for 70% of U.S. adults to have received at least one COVID-19 vaccine dose by July 4, 2021. Therefore, it is recommended that the Plan use this benchmark goal to set the same target rate of 70% by July 4, 2021.

Developmental Screening PIP

Through a review conducted in February 2021, IPRO determined that the following validation elements of the <u>Developmental Screening baseline report</u> submitted by ACLA did not achieve full compliance:

1c: Partially Met. It is recommended that the PIP Report section, "Describe high-volume or high-risk conditions addressed", reports the prevalence of developmental disorders by condition (ICD-10 codes F80-F89). In addition, for the sum total of children with developmental disorders, if feasible, report rates for IEP referral/engagement, stratified by geographic region, age group and race/ethnicity. A brief interpretation of the data should be included.

3c: Partially Met. Planned IRR procedures merit elaboration in the validity and reliability section of the PIP Report (e.g., chart abstraction tool, training and instructions, IRR process, process to ensure IRR feedback correction of items not meeting IRR).

3d: Not Met. The planned chart review sampling methodology was not explained. If the methodology is pending a determination of limitations imposed by COVID-19, possible alternatives to a random sample should be considered. For example, if the Plan will use an existing record sample, was that sample randomly

selected? Does that sample represent the PIP eligible population? Further discussion is merited at the next Collaborative PIP meeting.

4b: Not Met. Table 4 does not include any barrier analyses to inform initial interventions. Might there be existing surveys, such as CAHPS, that identify barriers that might inform interventions? In addition, the data collection procedure section merits a summary of how direct member input will be obtained on an ongoing basis (e.g., from care management outreach and/or meetings attended by members) to identify and address barriers with modified interventions for continuous improvement. The first quarterly update report provides an opportunity to address this comment. In addition, further discussion is merited at the next Collaborative PIP meeting.

4c: Partially Met. Although the data collection procedure does summarize plans for obtaining provider feedback on barriers, Table 4 does not include any barrier analyses to inform initial interventions. Are there scheduled meetings and/or provider outreach than provide opportunities for provider input about barriers and opportunities for improvement? The first quarterly update report provides an opportunity to address this comment. In addition, further discussion is merited at the next Collaborative PIP meeting.

5a: Partially Met. The interventions described are pertinent to the known barriers and, as the PIP proceeds, the provider and member feedback obtained as well as stratified data on susceptible subpopulations (e.g., children without six or more well-child visits during the first 15 months of life [HEDIS W15]) can be used to inform interventions that are tailored to the Plan's members' needs. The worksheet for Analysis of Disproportionate Under-Representation-6+ Well-Child Visits First 15 months of life (HEDIS W15) provides a tool for MCOs to identify these susceptible subgroups, then develop and implement tailored and targeted interventions. The first quarterly update report provides an opportunity to address this comment. In addition, further discussion is merited at the next Collaborative PIP meeting. **Table 5** provides a summary of ACLA's PIPs for 2020–2021.

Table 5: ACLA PIP Summaries, 2020–2021

ACLA PIP Summaries

PIP 1: Improving Rates for (1) Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment (IET) and (2) Follow-Up After Emergency Department Visit for Alcohol and Other Drug Abuse or Dependence **Validation Summary:** The validation findings generally indicate that the credibility of the PIP results is not at risk.

Aim

The overall aim is to improve the rate of Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment (IET; HEDIS 2020) and to improve the rates for Follow-Up After Emergency Department Visit for Alcohol and Other Drug Abuse or Dependence (FUA; HEDIS 2020), as well as Pharmacotherapy for Opioid Use Disorder (POD) by implementing enhanced interventions.

Interventions

- 1. Conduct provider training to expand the workforce for treatment initiation, follow-up, and continuity of pharmacotherapy for Opioid Use Disorder (POD), and encourage provider enrollment in the following training programs:
 - The American Society of Addiction Medicine (ASAM) National Practice Guideline For the Treatment of Opioid Use Disorder, 2020 Focused Update (hard copy + web-based learning)
 - Treatment of Opioid Use Disorder Course (includes training for the waiver to prescribe buprenorphine) —
 ASAM; Targeted providers to include: PCPs, pediatricians, obstetricians, ER physicians, FQHC and urgent care providers.
 - Fundamentals of Addiction Medicine (ASAM); Targeted providers to include psychiatrists, pediatricians, LMHPs, PCPs, obstetricians, ER physicians, FQHC and urgent care providers.
 - The ASAM Criteria Course for appropriate levels of care; Targeted providers to include LMHPs, PCPs,

ACLA PIP Summaries

- pediatricians, obstetricians, ER physicians, FQHC and urgent care providers
- ASAM Motivational Interviewing Workshop; Targeted providers to include LMHPs, PCPs, pediatricians, obstetricians, ER physicians, FQHC and urgent care providers
- 2. Link primary care providers for youth and adults to resources from the Substance Abuse and Mental Health Services Administration (SAMHSA) Resources for Screening, Brief Intervention, and Referral to Treatment (SBIRT) (https://www.samhsa.gov/sbirt/resources) and encourage primary care conduct of SBIRT for youth and adults; Targeted providers to include pediatricians, LMHPs, PCPs, obstetricians, ER physicians, FQHC and urgent care providers.
- 3. Partner with hospitals/EDs to improve timely initiation and engagement in treatment (e.g., MCO liaisons, hospital initiatives, ED protocols); and
- 4. Provide MCO enhanced care coordination (e.g., behavioral health integration, case management, and improved communication between MCO UM and CM for earlier notification of hospitalization, improved discharge planning practices and support, such as recovery coaches, and coordinate with pharmacists).

Performance Improvement Summary

Strengths: The following performance indicators represent strengths because they showed improvement from baseline to final remeasurement of at least 3 percentage points¹:

- Indicator 5: Engagement of AOD Treatment: Total age groups, Opioid abuse or dependence diagnosis cohort
- Indicator 7: The percentage of emergency department (ED) visits for members 13 years of age and older with a
 principal diagnosis of alcohol or other drug (AOD) abuse or dependence who had a follow-up visit for AOD within 30
 days of the ED visit

Opportunities for Improvement: The following performance indicators represent opportunities for improvement because they did not show improvement from baseline to final remeasurement of at least 3 percentage points:

- Indicator 1: Initiation of AOD Treatment: Total age groups, Alcohol abuse or dependence diagnosis cohort
- Indicator 2: Initiation of AOD Treatment: Total age groups, Opioid abuse or dependence diagnosis cohort
- Indicator 3: Initiation of AOD Treatment: Total age groups, Total diagnosis cohort
- Indicator 4: Engagement of AOD Treatment: Total age groups, Alcohol abuse or dependence diagnosis cohort
- Indicator 6: Engagement of AOD Treatment: Total age groups, Total diagnosis cohort
- Indicator 8: The percentage of emergency department (ED) visits for members 13 years of age and older with a principal diagnosis of alcohol or other drug (AOD) abuse or dependence who had a follow-up visit for AOD within 7 days of the ED visit

IPRO PIP validation review and LDH's subject matter expert review of the PIP Report submitted on 12/31/20 also identified the following opportunities for improvement, and shared this feedback with the plan:

- The MCO was advised to obtain direct member feedback from Care Management outreach in response to poorly performing ITMs.
- There is an opportunity to derive updated barrier analysis information by conducting focus groups with provider organizations.
- There is an opportunity to address geographic disparity areas identified in the driver diagram by implementing PIP interventions in those areas.
- ITMs indicate that members with co-morbid serious mental illness are more successfully outreached and receiving
 follow-up compared to those with SUD. There is an opportunity to add an intervention to improve member receipt
 of psychosocial SUD treatment.
- Indicator 8 did not have the correct denominator in the results table.

ACLA PIP Summaries

PIP 2: Improve Screening for Chronic Hepatitis C Virus (HCV) and Pharmaceutical Treatment Initiation **Validation Summary:** The validation findings generally indicate that the credibility of the PIP results is not at risk.

Δim

Improve the Healthy Louisiana HCV screening rate and initiation of HCV pharmaceutical treatment rate by ten percentage points by implementing a robust set of interventions to address the following key intervention objectives:

- 1. Member Intervention Objective: Outreach and educate eligible members, and facilitate referrals to/schedule appointments with (I) PCPs for screening and (II) HCV providers (priority; per OPH database) or PCPs (per member preference) for treatment, with tailored interventions targeted to each of the following high-risk subpopulations (which are not mutually exclusive, as enrollees may have multiple high-risk characteristics):
 - Beneficiaries born between the years 1945 and 1965
 - Current or past injection drug use
 - Persons ever on long term hemodialysis
 - Persons who were ever incarcerated
 - Persons with HIV infection
- 2. Provider Intervention Objective: Educate providers on evidence-based recommendations and availability of HCV specialty providers (United States Preventive Services Task Force, 2013; American Association for the Study of Liver Diseases/Infectious Diseases Society of America, 2018), and coordinate referrals for screening and treatment.

Interventions

- 1. Enhanced Case Management Outreach for HCV Treatment Initiation
- 2. Enhanced Case Management Outreach for HCV Screening / Treatment Initiation
- 3. Enhanced Case Management Outreach for HCV Screening
- 4. Provider education regarding Sofosbuvir/Epitasis 400/100 (AG Epclusa®: Preferred) prescription.
- 5. DAA Treatment Initiation of OPH Confirmed / Probable Members
- 6. Enhanced Member Outreach to Increase Awareness of HCV Screening / Treatment Initiative via Mailed Member Newsletter
- 7. Enhanced Member Outreach to Increase Awareness of HCV Screening / Treatment Initiative via Texting Campaign

Performance Improvement Summary

Strengths: The following performance indicators demonstrated improvement of at least 3 percentage points from baseline to final remeasurement¹:

- Performance Indicator 1a (Universal Screening)
- Performance Indicator 1b (Birth Cohort Screening)
- Performance Indicator 2a (Non-Birth Cohort/Risk Factor Screening- ever screened)
- Performance Indicator 3a (HCV Treatment Initiation Overall)
- Performance Indicator 3b (HCV Treatment Initiation Drug Users)
- Performance Indicator 3c (HCV Treatment Initiation Persons with HIV)

Opportunities for improvement: The following performance indicators did not demonstrate improvement of at least 3 percentage points from baseline to final remeasurement:

Performance Indicator 2b (Non-Birth Cohort/Risk Factor Screening- Annual Screening)

IPRO PIP validation review and LDH's subject matter expert review of the PIP Report submitted on 12/31/20 also identified the following opportunities for improvement, and shared this feedback with the plan:

- There was an opportunity to conduct a systematic barrier analysis to identify susceptible subpopulations.
- There was an opportunity to stratify performance indicators by member characteristics such as geographic area.
- An ITM for Intervention 2a was incorrectly calculated.
- There were discrepancies in the denominator of performance indicator 3 (OPH).

ACLA PIP Summaries

PIP 3: Ensuring access to the COVID-19 vaccine among Healthy Louisiana vaccine-eligible enrollees: Persons 18 years of age or older

Validation Summary: N/A (the project was not completed until 12/31/2021)

Aim

Ensure access to COVID-19 vaccination for Healthy Louisiana enrollees.

Interventions

- 1. CM Managers will telephonically outreach to members enrolled in CM to assist with scheduling vaccine appointment.
- 2. Care Coordinator and Community Navigators will telephonically outreach members not enrolled in CM to assist with scheduling vaccine appointment.
- 3. One week prior to due for 2nd dose administration and overdue 2nd dose, a telephonic outreach will be utilized to remind and assist members with obtaining 2nd dose. This outreach is being performed by Case Managers, Care Coordinators and Community Navigators.
- 4. Spanish-speaking Community Health Educators to engage with Spanish-speaking enrollees and assist with the transportation benefit provided through ACLA.
- 5. Provide transportation for enrollees reporting transportation difficulty.
- 6. Work with providers to assist homebound members with receiving the vaccination.

Performance Improvement Summary

Not yet available.

PIP 4: Improving Receipt of Global Developmental Screening in the First Three Years of Life **Validation Summary:** N/A.

Aim

Increase the percentage of children screened for risk of developmental, behavioral and social delays using a standardized global developmental screening tool in the 12 months preceding or on their first, second or third birthday.

Interventions

- 1. Conduct provider education on standardized global developmental screening tools, new billing guidelines for coding developmental screening, and early intervention programs.
- 2. Develop member gap reports, stratify by provider and distribute to providers.
- 3. Conduct enhanced care coordination outreach/education to parents of members on gap report.
- 4. Conduct a PCP chart review of:
 - random sample of 30 eligible population charts with CPT® Code 96110 to validate whether the tools in Table 4a were utilized for global developmental screening.
 - random sample of 30 eligible population charts without CPT Code 96110 to discern whether the tools in Table 4a were utilized for global developmental screening at the child's 9-month, 18-month or 30-month visit.
- 5. Collaborate with early intervention programs (EIP) and coordinate with providers to facilitate referrals from providers to EIP.

Performance Improvement Summary

Not yet available.

ACLA: AmeriHealth Caritas Louisiana; PIP: performance improvement project; HEDIS: Healthcare Effectiveness Data and Information Set; PCP: primary care provider; ER: emergency room; FQHC: federally qualified health centers; LMHP: licensed mental health professional; MCO: managed care organization; ED: emergency department; UM: Utilization Management; CM: Care Management; ITM: intervention tracking measure; SUD: substance use disorder; OPH: Office of Public Health; DAA: direct-acting antiviral; HIV: human immunodeficiency virus; LDH: Louisiana Department of Health; COVID-19: 2019 novel coronavirus; N/A: not applicable; CPT: Current Procedural Terminology.

¹The final interim rates reported extend past the ATR review period (July 1 2019 – June 30 2020). This allowed for sufficient data to be reported to draw conclusions about the PIP.

Table 6 shows IPRO's assessment of PIP indicator performance for MY 2020 by topic.

Table 6: Assessment of AHCLA PIP Indicator Performance – Measurement Year 2 (2020)

Indicator # Indicator Description PIP 1: Improving Rates for (1) Initiation and Engagement of AOD Abuse or Dependence Treatment (IET) and (2) Follow-Up After ED Visit for AOD Abuse or Dependence 1 Initiation of AOD Treatment: Total age groups, Alcohol abuse or dependence diagnosis cohort Baseline: 55.86% Final: 56.25% Target: 63.76% 2 Initiation of AOD Treatment: Total age groups, Opioid abuse or dependence diagnosis cohort Baseline: 72.23% Final: 71.12% Target: 77.06% 3 Initiation of AOD Treatment: Total age groups, Total diagnosis cohort Baseline: 61.56% Final: 58.79% Target: 65.64% 4 Engagement of AOD Treatment: Total age groups, Alcohol abuse or dependence diagnosis cohort Baseline: 17.72% Final: 17.01% Target: 23.89% 5 Engagement of AOD Treatment: Total age groups, Opioid abuse or dependence diagnosis cohort Baseline: 31.09% Final: 36.68%
PIP 1: Improving Rates for (1) Initiation and Engagement of AOD Abuse or Dependence Treatment (IET) and (2) Follow-Up After ED Visit for AOD Abuse or Dependence 1 Initiation of AOD Treatment: Total age groups, Alcohol abuse or dependence diagnosis cohort Baseline: 55.86% Final: 56.25% Target: 63.76% 2 Initiation of AOD Treatment: Total age groups, Opioid abuse or dependence diagnosis cohort Baseline: 72.23% Final: 71.12% Target: 77.06% 3 Initiation of AOD Treatment: Total age groups, Total diagnosis cohort Baseline: 61.56% Final: 58.79% Target: 65.64% 4 Engagement of AOD Treatment: Total age groups, Alcohol abuse or dependence diagnosis cohort Baseline: 17.72% Final: 17.01% Target: 23.89% 5 Engagement of AOD Treatment: Total age groups, Opioid abuse or dependence diagnosis cohort Baseline: 17.72% Final: 17.01% Target: 23.89% 5 Engagement of AOD Treatment: Total age groups, Opioid abuse or dependence diagnosis cohort Baseline: 31.09% Target not met, and performance decline demonstrated. Target not met, but performance decline demonstrated. Target not met, and performance decline demonstrated.
AOD Abuse or Dependence Treatment (IET) and (2) Follow-Up After ED Visit for AOD Abuse or Dependence 1 Initiation of AOD Treatment: Total age groups, Alcohol abuse or dependence diagnosis cohort Baseline: 55.86% Final: 56.25% Target: 63.76% 2 Initiation of AOD Treatment: Total age groups, Opioid abuse or dependence diagnosis cohort Baseline: 72.23% Final: 71.12% Target: 77.06% 3 Initiation of AOD Treatment: Total age groups, Total diagnosis cohort Baseline: 61.56% Final: 58.79% Target: 65.64% 4 Engagement of AOD Treatment: Total age groups, Alcohol abuse or dependence diagnosis cohort Baseline: 17.72% Final: 17.01% Target: 23.89% 5 Engagement of AOD Treatment: Total age groups, Opioid abuse or dependence diagnosis cohort Baseline: 13.09% Target not met, and performance decline demonstrated. Target not met, but performance decline demonstrated. Target not met, and performance decline demonstrated. Target not met, and performance decline demonstrated.
1 Initiation of AOD Treatment: Total age groups, Alcohol abuse or dependence diagnosis cohort Baseline: 55.86% Final: 56.25% Target: 63.76% 2 Initiation of AOD Treatment: Total age groups, Opioid abuse or dependence diagnosis cohort Baseline: 72.23% Final: 71.12% Target: 77.06% 3 Initiation of AOD Treatment: Total age groups, Total diagnosis cohort Baseline: 61.56% Final: 58.79% Target: 65.64% 4 Engagement of AOD Treatment: Total age groups, Alcohol abuse or dependence diagnosis cohort Baseline: 17.72% Final: 17.01% Target: 23.89% 5 Engagement of AOD Treatment: Total age groups, Opioid abuse or dependence diagnosis cohort Baseline: 31.09% Target not met, and performance decline demonstrated. Target not met, and performance decline demonstrated.
or dependence diagnosis cohort Baseline: 55.86% Final: 56.25% Target: 63.76% 2 Initiation of AOD Treatment: Total age groups, Opioid abuse or dependence diagnosis cohort Baseline: 72.23% Final: 71.12% Target: 77.06% 3 Initiation of AOD Treatment: Total age groups, Total diagnosis cohort Baseline: 61.56% Final: 58.79% Target: 65.64% 4 Engagement of AOD Treatment: Total age groups, Alcohol abuse or dependence diagnosis cohort Baseline: 17.72% Final: 17.01% Target: 23.89% 5 Engagement of AOD Treatment: Total age groups, Opioid abuse or dependence diagnosis cohort Baseline: 31.09% Target not met, and performance decline demonstrated. Target not met, and performance decline demonstrated.
Baseline: 55.86% Final: 56.25% Target: 63.76% 2 Initiation of AOD Treatment: Total age groups, Opioid abuse or dependence diagnosis cohort Baseline: 72.23% Final: 71.12% Target: 77.06% 3 Initiation of AOD Treatment: Total age groups, Total diagnosis cohort Baseline: 61.56% Final: 58.79% Target: 65.64% 4 Engagement of AOD Treatment: Total age groups, Alcohol abuse or dependence diagnosis cohort Baseline: 17.72% Final: 17.01% Target: 23.89% 5 Engagement of AOD Treatment: Total age groups, Opioid abuse or dependence diagnosis cohort Baseline: 31.09% Target not met, and performance decline demonstrated. Target not met, and performance decline demonstrated. Target not met, and performance decline demonstrated.
Final: 56.25% Target: 63.76% 2 Initiation of AOD Treatment: Total age groups, Opioid abuse or dependence diagnosis cohort Baseline: 72.23% Final: 71.12% Target: 77.06% 3 Initiation of AOD Treatment: Total age groups, Total diagnosis cohort Baseline: 61.56% Final: 58.79% Target: 65.64% 4 Engagement of AOD Treatment: Total age groups, Alcohol abuse or dependence diagnosis cohort Baseline: 17.72% Final: 17.01% Target: 23.89% 5 Engagement of AOD Treatment: Total age groups, Opioid abuse or dependence diagnosis cohort Baseline: 31.09% Target not met, and performance decline demonstrated. Target not met, and performance decline demonstrated.
Target: 63.76% 2 Initiation of AOD Treatment: Total age groups, Opioid abuse or dependence diagnosis cohort Baseline: 72.23% Final: 71.12% Target: 77.06% 3 Initiation of AOD Treatment: Total age groups, Total diagnosis cohort Baseline: 61.56% Final: 58.79% Target: 65.64% 4 Engagement of AOD Treatment: Total age groups, Alcohol abuse or dependence diagnosis cohort Baseline: 17.72% Final: 17.01% Target: 23.89% 5 Engagement of AOD Treatment: Total age groups, Opioid abuse or dependence diagnosis cohort Baseline: 31.09% Target not met, and performance decline demonstrated. Target not met, and performance decline demonstrated. Target not met, and performance decline demonstrated.
Initiation of AOD Treatment: Total age groups, Opioid abuse or dependence diagnosis cohort Baseline: 72.23% Final: 71.12% Target: 77.06% Initiation of AOD Treatment: Total age groups, Total diagnosis cohort Baseline: 61.56% Final: 58.79% Target: 65.64% Engagement of AOD Treatment: Total age groups, Alcohol abuse or dependence diagnosis cohort Baseline: 17.72% Final: 17.01% Target: 23.89% Engagement of AOD Treatment: Total age groups, Opioid abuse or dependence diagnosis cohort Baseline: 31.09% Target not met, and performance decline demonstrated. Target not met, and performance decline demonstrated. Target not met, and performance decline demonstrated.
dependence diagnosis cohort Baseline: 72.23% Final: 71.12% Target: 77.06% 3 Initiation of AOD Treatment: Total age groups, Total diagnosis cohort Baseline: 61.56% Final: 58.79% Target: 65.64% 4 Engagement of AOD Treatment: Total age groups, Alcohol abuse or dependence diagnosis cohort Baseline: 17.72% Final: 17.01% Target: 23.89% 5 Engagement of AOD Treatment: Total age groups, Opioid abuse or dependence diagnosis cohort Baseline: 31.09% Target not met, and performance decline demonstrated. Target not met, and performance decline demonstrated. Target not met, but performance improvement demonstrated.
Baseline: 72.23% Final: 71.12% Target: 77.06% 3
Final: 71.12% Target: 77.06% 3 Initiation of AOD Treatment: Total age groups, Total diagnosis cohort Baseline: 61.56% Final: 58.79% Target: 65.64% 4 Engagement of AOD Treatment: Total age groups, Alcohol abuse or dependence diagnosis cohort Baseline: 17.72% Final: 17.01% Target: 23.89% 5 Engagement of AOD Treatment: Total age groups, Opioid abuse or dependence diagnosis cohort Baseline: 31.09% Target not met, and performance decline demonstrated. Target not met, and performance decline demonstrated.
Target: 77.06% Initiation of AOD Treatment: Total age groups, Total diagnosis cohort Baseline: 61.56% Final: 58.79% Target: 65.64% 4 Engagement of AOD Treatment: Total age groups, Alcohol abuse or dependence diagnosis cohort Baseline: 17.72% Final: 17.01% Target: 23.89% 5 Engagement of AOD Treatment: Total age groups, Opioid abuse or dependence diagnosis cohort Baseline: 31.09% Target not met, and performance decline demonstrated. Target not met, and performance decline demonstrated.
Initiation of AOD Treatment: Total age groups, Total diagnosis cohort Baseline: 61.56% Final: 58.79% Target: 65.64% 4 Engagement of AOD Treatment: Total age groups, Alcohol abuse or dependence diagnosis cohort Baseline: 17.72% Final: 17.01% Target: 23.89% 5 Engagement of AOD Treatment: Total age groups, Opioid abuse or dependence diagnosis cohort Baseline: 31.09% Target not met, and performance decline demonstrated. Target not met, and performance decline demonstrated.
cohort Baseline: 61.56% Final: 58.79% Target: 65.64% 4 Engagement of AOD Treatment: Total age groups, Alcohol abuse or dependence diagnosis cohort Baseline: 17.72% Final: 17.01% Target: 23.89% 5 Engagement of AOD Treatment: Total age groups, Opioid abuse or dependence diagnosis cohort Baseline: 31.09% Target not met, and performance decline demonstrated. Target not met, but performance improvement demonstrated.
Final: 58.79% Target: 65.64% 4 Engagement of AOD Treatment: Total age groups, Alcohol abuse or dependence diagnosis cohort Baseline: 17.72% Final: 17.01% Target: 23.89% 5 Engagement of AOD Treatment: Total age groups, Opioid abuse or dependence diagnosis cohort Baseline: 31.09% Target not met, and performance decline demonstrated. Target not met, but performance improvement demonstrated.
Target: 65.64% 4 Engagement of AOD Treatment: Total age groups, Alcohol abuse or dependence diagnosis cohort Baseline: 17.72% Final: 17.01% Target: 23.89% 5 Engagement of AOD Treatment: Total age groups, Opioid abuse or dependence diagnosis cohort Baseline: 31.09% Target not met, and performance decline demonstrated. Target not met, but performance improvement demonstrated.
4 Engagement of AOD Treatment: Total age groups, Alcohol abuse or dependence diagnosis cohort Baseline: 17.72% Final: 17.01% Target: 23.89% 5 Engagement of AOD Treatment: Total age groups, Opioid abuse or dependence diagnosis cohort Baseline: 31.09% Target not met, and performance decline demonstrated. Target not met, but performance improvement demonstrated.
abuse or dependence diagnosis cohort Baseline: 17.72% Final: 17.01% Target: 23.89% 5 Engagement of AOD Treatment: Total age groups, Opioid abuse or dependence diagnosis cohort Baseline: 31.09% Target not met, but performance improvement demonstrated.
Baseline: 17.72% Final: 17.01% Target: 23.89% 5 Engagement of AOD Treatment: Total age groups, Opioid abuse or dependence diagnosis cohort Baseline: 31.09% Target not met, but performance improvement demonstrated.
Final: 17.01% Target: 23.89% 5 Engagement of AOD Treatment: Total age groups, Opioid abuse or dependence diagnosis cohort Baseline: 31.09% Target not met, but performance improvement demonstrated.
Target: 23.89% Engagement of AOD Treatment: Total age groups, Opioid abuse or dependence diagnosis cohort Baseline: 31.09% Target not met, but performance improvement demonstrated.
5 Engagement of AOD Treatment: Total age groups, Opioid abuse or dependence diagnosis cohort Baseline: 31.09% Target not met, but performance improvement demonstrated.
abuse or dependence diagnosis cohort Baseline: 31.09% improvement demonstrated.
Baseline: 31.09%
i iliai. Juluo/u
Target: 40.83%
6 Engagement of AOD Treatment: Total age groups, Total Target not met, and performance
diagnosis cohort decline demonstrated.
Baseline: 22.17%
Final: 20.1%
Target: 27.14%
7 The percentage of ED visits for members 13 years of age and Target not met, but performance
older with a principal diagnosis of AOD abuse or dependence improvement demonstrated.
who had a follow-up visit within 30 days of the ED visit Baseline: 9.86%
Final: 13.67%
Target: 26.55%
8 The percentage of ED visits for members 13 years of age and Target not met, but performance
older with a principal diagnosis of AOD abuse or dependence improvement demonstrated.
who had a follow up visit within 7 days of the ED visit
Baseline: 5.46%
Final: 8.29%
Target: 16.97%

Indicator #	Indicator Description	Assessment of Performance, Baseline to Final
	PIP 2: Improve Screening for Chronic Hepatitis C Virus and	
	Pharmaceutical Treatment Initiation	
1 a	Universal Screening	Target not met, but performance
	Baseline: 15.47%	improvement demonstrated.
	Final: 19.01%	
	Target: 30.47%	
1b	Birth Cohort Screening	Target met and performance
	Baseline: 8.53%	improvement demonstrated.
	Final: 25.85%	
	Target: 23.53%	
2a	Non-Birth Cohort/Risk Factor Screening- ever screened	Target met and performance
	Baseline: 10.99%	improvement demonstrated.
	Final: 30.19%	
	Target: 25.99%	
2b	Non-Birth Cohort/Risk Factor Screening- Annual Screening	Target not met, and performance
	Baseline: 10.37%	decline demonstrated.
	Final: 10.22%	
	Target: 25.37%	
3a	HCV Treatment Initiation-Overall	Target not met, but performance
	Baseline: 13.91%	improvement demonstrated.
	Final: 18.09%	
	Target: 28.91%	
3b	HCV Treatment Initiation-Drug Users	Target not met, but performance
	Baseline: 12.92%	improvement demonstrated.
	Final: 17.65%	
	Target: 27.92%	
3c	HCV Treatment Initiation-Persons with HIV	Target not met, but performance
	Baseline: 17.26%	improvement demonstrated.
	Final: 26.41%	
	Target: 32.26%	

AHCLA: AmeriHealth Caritas Louisiana; PIP: performance improvement project; AOD: Alcohol or Other Drug; ED: emergency department; HCV: chronic hepatitis C; HIV/AIDS: human immunodeficiency virus/acquired immune deficiency syndrome; red: target not met, and performance decline demonstrated; yellow: target not met, but performance improvement demonstrated; green: target met and performance improvement demonstrated.

IV. Review of Compliance with Medicaid and CHIP Managed Care Regulations

Objectives

Federal regulations at 42 CFR 438.358 delineate that a review of an MCO's compliance with standards established by the state to comply with the requirements of § 438 Subpart E is a mandatory EQR activity. Further, this review must be conducted within the previous 3-year period, by the state, its agent, or the EQRO.

LDH annually evaluates the MCO's performance against contract requirements and state and federal regulatory standards through its EQRO, as well as by an examination of each MCO's accreditation review findings.

IPRO conducted Compliance Audits on behalf of the LDH in 2019 and 2020. Full compliance audits occur every 3 years, with partial audits occurring within the intervening years. The last full compliance audit occurred in 2019. The 2020 annual compliance audit was a partial review of each MCO's compliance with contractual requirements during the period of April 1, 2019, through March 31, 2020.

The next full audit is scheduled for July/August 2022, covering the time period January 1, 2021, to December 31, 2021.

Technical Methods of Data Collection and Analysis

To determine which regulations must be reviewed annually, IPRO performs an assessment of the MCO's performance on each of the federal managed care regulations over the prior three-year period. Results of both the EQRO reviews and accreditation survey are examined. The following guidelines are used to determine which areas are due for assessment:

- regulations for which accrediting organization standards have been cross-walked and do not fully meet equivalency with federal requirements;
- regulations that are due for evaluation, based on the three-year cycle;
- regulations for which the MCO received less than full compliance on the prior review by either the EQRO or accrediting organization;
- state- and contract-specific requirements beyond the federal managed care regulatory requirements;
- areas of interest to the state, or noted to be at risk by either the EQRO and/or state; and
- note that Quality Management: Measurement and Improvement Quality Assessment and Performance improvement (QAPI; 42 CFR 438.240) is assessed annually, as is required by federal regulations.

In developing its review protocols, IPRO followed a detailed and defined process, consistent with the CMS EQRO protocols for monitoring regulatory compliance of MCOs. For each set of standards reviewed, IPRO prepared standard-specific review tools with standard-specific elements (i.e., sub-standards). The tools include the following:

- statement of federal regulation and related federal regulations;
- statement of state regulations;
- statement of state and MCO contract requirement(s);
- suggested evidence;
- reviewer determination;
- prior results;
- descriptive reviewer findings and comments related to findings; and
- MCO response and action plan.

IPRO's Compliance Audit included a comprehensive evaluation of policies, procedures, files and other materials corresponding to the following 11 domains:

- 1. Availability of services
- 2. Assurances of adequate capacity and services
- 3. Coordination and continuity of care
- 4. Coverage and authorization of services
- 5. Provider selection
- 6. Confidentiality
- 7. Grievance and appeal systems
- 8. Subcontractual relationships and delegation
- 9. Practice guidelines
- 10. Health information systems
- 11. QAPI

During these audits, determinations of full compliance, substantial compliance, minimal compliance and compliance not met were used for each element under review. Definitions for these review determinations are presented in **Table 7**.

Table 7: Review Determination Definitions

Level of Compliance	Meaning
Full compliance	MCO has met or exceeded the standard
Substantial	The MCO has met most of the requirements of the standard but has minor deficiencies.
Minimal	The MCO has met some of the requirements of the standard, but has significant
Millimai	deficiencies that require corrective action
Not Met	MCO has not met the standard

MCO: managed care organization.

During this review period, Magellan was the only behavioral health PAHP and MCNA was the only dental PAHP. The PAHPs have different compliance requirements than the MCO so they are not compared directly to the MCO in this report.

Description of Data Obtained

In advance of the review, IPRO requested documents relevant to each standard under review to support each MCO's compliance with federal and state regulations and contract requirements. This included items such as: policies and procedures; sample contracts; annual QI program description, work plan, and annual evaluation; member and provider handbooks; access reports; committee descriptions and minutes; case files; program monitoring reports; and evidence of monitoring, evaluation, analysis, and follow-up. Supplemental documentation was also requested for areas where IPRO deemed it necessary to support compliance.

Conclusions

ACLA demonstrated full compliance in all 11 domains except for assurances of adequate capacity and services. A crosswalk of CFR standard names, CFR citations, and compliance levels of each MCO is presented in **Table 8**.

Table 8: CFR Standards to State Contract Crosswalk

CFR Standard Name	CFR Citation	ACLA
Availability of services	438.206	Full
Assurances of adequate capacity and services	438.207	Full
	438.680	Substantial
Coordination and continuity of care	438.208	Full
Coverage and authorization of services	438.114	Full
	438.404	Full
	438.210	Full
Provider selection	438.214	Full
Confidentiality	438.224	Full
	438.56	Full
	438.100	Full
	438.10	Full
Grievance and appeal systems	438.228	Full
	438.402	Full
	438.406	Full
	438.408	Full
	438.410	Full
	438.420	Full
	438.424	Full
Subcontractual relationships and delegation	438.230	Full
Practice guidelines	438.236	Full
Health information systems	438.242	Full
QAPI	438.330	Full
	438.240	Full
	438.242	Full

CFR: Code of Federal Regulations; ACLA: AmeriHealth Caritas Louisiana; QAPI: Quality Assurance and Performance Improvement.

Findings by Domain

Domain: Adequate Capacity and Service

- Distance and/or time requirements were not met for urban and rural parishes.
- The MCO did not provide evidence that "the plan shall specifically assess the extent to which the MCO's instate network is sufficient to meet the needs of this population."

V. Validation of Performance Measures

Objectives

Federal requirements from the Balanced Budget Act of 1997 (BBA), as specified within the CFR at 42 CFR 438.358, require that states ensure their MCOs collect and report performance measures annually. The requirement allows states, agents that are not managed care organizations, or an EQRO to conduct the performance measure validation (PMV). LDH contracted with IPRO to conduct the functions associated with validating PMs.

LDH has established quality measures and standards to evaluate MCO performance in key program areas. The selected measures align with specific priorities, goals, and/or focus areas of the Louisiana Medicaid Quality Strategy and include measures in the HEDIS.

Performance results can be calculated and reported to the state by the managed care organization, or the state can calculate the managed care organization's performance measure results for the preceding 12 months. LDH required its Medicaid MCOs to calculate their own performance measures rates and have them audited by an NCQA Certified Auditor.

Technical Methods of Data Collection and Analysis

Each MCO contracted with an independent licensed organization (LO) and underwent an NCQA HEDIS Compliance Audit for HEDIS MY 2020. To ensure that each MCO calculated its rates based on complete and accurate data and according to NCQA's established standards and that each MCO's independent auditors performed the audit using NCQA's guidelines, IPRO reviewed the final audit reports (FARs) produced for each MCO by the MCO's independent auditor. Once the MCOs' compliance with NCQA's established standards was examined, IPRO objectively analyzed the MCOs' HEDIS MY 2020 results and evaluated each MCO's current performance levels relative to *Quality Compass* national Medicaid percentiles.

IPRO evaluated each MCO's IS capabilities for accurate HEDIS reporting. This evaluation was accomplished by reviewing each FAR submitted by the MCOs that contained the LO's assessment of IS capabilities. The evaluation specifically focused on aspects of the MCO's system that could affect the HEDIS Medicaid reporting set.

The term "IS" – Information Systems – included the computer and software environment, data collection procedures, and abstraction of medical records for hybrid measures. The IS evaluation included a review of any manual processes used for HEDIS reporting. The LOs determined the extent to which the MCOs had the automated systems, information management practices, processing environment, and control procedures to capture, access, translate, analyze, and report each HEDIS measure.

In accordance with the MY 2020 NCQA *HEDIS Compliance Audit: Standards, Policies, and Procedures,* Volume 5, the LOs evaluated compliance with NCQA's IS standards. NCQA's IS standards detail the minimum requirements of an MCO's IS, as well as criteria that must be met for any manual processes used to report HEDIS information.

For each HEDIS measure, the MCO was evaluated on how their rate compared to the HEDIS MY 2020 *Quality Compass* national Medicaid HMO 50th percentile.

Description of Data Obtained

IPRO used the Final Audit Report (FAR) and the MCO rates provided on the Interactive Data Submission System (IDSS) file as the primary data sources. The FAR includes information on the MCOs' IS capabilities, findings for each measure, supplemental data validation results, medical record review validation (MRRV) results, results of any corrected programming logic (including corrections to numerators, denominators, or sampling used for final measure calculation), and opportunities for improvement. The final audit results included final determinations of validity made by the auditor for each performance measure. The IDSS file detailed all rates that were submitted to NCQA and whether the auditor deemed them to be reportable. The IDSS file is "locked" by the auditor so that no changes can be made to the results.

Conclusions

The MCO's independent auditors determined that the rates reported by the MCOs were calculated in accordance with NCQA's defined specifications and there were no data collection or reporting issues identified by the independent auditors.

Based on a review of the FARs issued by ACLA's independent auditor, IPRO found that ACLA was determined to be *fully compliant* with all seven of the applicable NCQA Information System (IS) standards. HEDIS rates produced by ACLA were reported to the NCQA. ACLA's compliance with IS standards is highlighted in **Table 9**.

Table 9: ACLA Compliance with Information System Standards – MY 2020

IS Standard	ACLA	
HEDIS Auditor		
1.0 Medical Services Data	Met	
2.0 Enrollment Data	Met	
3.0 Practitioner Data	Met	
4.0 Medical Record Review Processes	Met	
5.0 Supplemental Data	Met	
6.0 Data Preproduction Processing	Met	

MY: measurement year; IS: information system; ACLA: AmeriHealth Caritas Louisiana;

HEDIS: Healthcare Effectiveness Data and Information Set.

For SFY 2021, LDH required each contracted MCO to collect and report on 24 HEDIS measures that includes 66 total measures/submeasures indicators for HEDIS MY 2020 (measurement year 2020) specified in the provider agreement. The measurement set includes 13 incentive measures. **Table 10–Table 12** display the 66 measures indicators required by LDH. Red cells indicate that the measure fell below the NCQA 50th percentile, green indicates that the measure was at or above the 50th percentile. **Table 13** displays a summary of ACLA's HEDIS measure performance.

Table 10: ACLA HEDIS Effectiveness of Care Measures – MY 2020

HEDIS Measure	ACLA	Statewide Average
Adherence to Antipsychotic Medications for Individuals with Schizophrenia (SAA)	59.53%	53.40%
Antidepressant Medication Management (AMM)		
Effective Acute Phase Treatment	54.16%	53.24%
Effective Continuation Phase Treatment	38.61%	37.45%
Asthma Medication Ratio (AMR)		
Total	59.43%	65.24%
Breast Cancer Screening (BCS)	56.36%	55.43%
Cervical Cancer Screening (CCS)	54.77%	56.11%

HEDIS Measure	ACLA	Statewide Average
Childhood Immunization Status (CIS)		
Combo 2	74.45%	72.77%
Combo 3	71.53%	68.61%
Combo 4	70.07%	66.45%
Combo 5	62.29%	59.76%
Combo 6	32.12%	30.68%
Combo 7	61.56%	58.08%
Combo 8	31.63%	30.26%
Combo 9	28.71%	28.04%
Combo 10	28.71%	27.69%
DTaP	76.64%	74.04%
Hepatitis A	88.32%	83.76%
Hepatitis B	91.97%	92.28%
HiB	91.24%	89.61%
Influenza	35.52%	35.81%
IPV	92.21%	91.92%
MMR	90.51%	88.55%
Pneumococcal conjugate	78.10%	75.15%
Rotavirus	73.97%	73.13%
VZV	89.05%	88.27%
Chlamydia Screening in Women (CHL) – Total	63.51%	61.98%
Colorectal Cancer Screening (COL)	38.98%	36.06%
Comprehensive Diabetes Care (CDC)	30.30/0	30.00%
Comprehensive Diabetes Care (CDC) Comprehensive Diabetes Care (CDC)	50.36%	50.56%
Comprehensive Diabetes Care – Eye exam (retinal) performed Comprehensive Diabetes Care – HbA1c control (< 8.0%)	54.50% 41.85%	56.13% 40.62%
Comprehensive Diabetes Care – HbA1c control (< 8.0%) Comprehensive Diabetes Care – HbA1c poor control (> 9.0%)*	48.66%	
	81.75%	50.96%
Comprehensive Diabetes Care – HbA1c Testing (CDC) Controlling High Blood Pressure (CBP)	50.85%	81.74% 48.24%
	50.85%	48.24%
Diabetes screening for people with Schizophrenia or Bipolar who are using Antipsychotic medications (SSD)	79.21%	79.00%
Flu Vaccinations for Adults Ages 18 to 64 (FVA)	37.04%	35.78%
Follow-up After Hospitalization for Mental Illness (FUH)	37.0470	33.7670
Within 7 Days of Discharge	20.33%	21.66%
Within 7 Days of Discharge Within 30 Days of Discharge	41.99%	41.74%
Follow-up Care for Children Prescribed ADHD Medication (ADD)	41.3370	41.7470
Initiation Phase	40.17%	41.24%
Continuation Phase	56.38%	55.84%
Immunization Status for Adolescents (IMA)	30.3070	33.0470
Combo 1	86.75%	87.96%
Combo 2	45.58%	45.78%
HPV	46.46%	46.67%
Meningococcal	87.65%	88.78%
Tdap/Td	87.76%	89.06%
Medical Assistance with Smoking and Tobacco Use Cessation (MSC)	67.70/0	09.00/0
	71.68%	72.68%
Advising Smokers and Tobacco Users to Quit Discussing Cessation Medications	50.68%	
	42.15%	50.32% 46.05%
Discussing Cessation Strategies	42.13%	40.03%
Plan All-Cause Readmissions (PCR)	0.600/	0.500/
Expected Readmissions Rate	9.69%	9.59%

HEDIS Measure	ACLA	Statewide Average
Observed Readmission (Num/Den)	10.96%	10.28%
Observed-to-Expected Ratio (Observed Readmission/Expected Readmissions)	1.1304	1.0714
Statin Therapy for Patients with Cardiovascular Disease (SPC)		
Received Statin Therapy: Total	79.61%	80.00%
Statin Adherence 80%: Total	65.45%	64.45%
Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents Body Mass Index Assessment for		
Children/Adolescents (WCC)		
BMI percentile documentation	71.88%	67.84%
Counseling for nutrition	60.68%	62.72%
Counseling for physical activity	53.39%	53.57%

^{*} A lower rate is desirable.

HEDIS: Healthcare Effectiveness Data and Information Set; MY: measurement year; ACLA: AmeriHealth Caritas Louisiana; DTaP: diphtheria, tetanus, and acellular pertussis; HiB: Haemophilus influenzae type b; IPV: polio vaccine, inactivated; MMR: measles, mumps, and rubella; VZV: varicella-zoster virus; BP: blood pressure; HPV: human papillomavirus: Tdap/Td: tetanus, diphtheria, and pertussis/tetanus and diphtheria; BMI: body mass index; **bolded text**: incentive measure; green: >= 50th NCQA national benchmark; red: < 50th NCQA national benchmark.

Table 11: ACLA HEDIS Access to/Availability of Care Measures - MY 2020

HEDIS Measure	ACLA	Statewide Average
Adults' Access to Preventive/ Ambulatory Health Services (AAP)	74.56%	75.53%
Prenatal and Postpartum Care (PPC)		
Postpartum Care	78.42%	76.50%
Prenatal Care	83.88%	80.06%
Well-Child Visits in the First 30 Months of Life (W30)		
First 15 Months	55.88%	54.28%
15 Months-30 Months	66.08%	66.98%

ACLA: AmeriHealth Caritas Louisiana; HEDIS: Healthcare Effectiveness Data and Information Set; MY: measurement year; **bolded text**: incentive measure; green: >= 50th NCQA national benchmark; red: < 50th NCQA national benchmark.

Table 12: ACLA HEDIS Use of Services Measures - MY 2020

		Statewide
HEDIS Measure	ACLA	Average
Ambulatory Care (AMB)		
Emergency Department Visits/1,000 MM*	57.56	54.82
Outpatient Visits/1,000 MM	352.54	379.97
Child and Adolescent Well-Care Visits (WCV)		
3–11 years	51.29%	50.80%
12–17 years	49.03%	48.08%
18–21 years	27.66%	26.36%
Total	46.49%	45.81%

^{*} A lower rate is desirable.

ACLA: AmeriHealth Caritas Louisiana; HEDIS: Healthcare Effectiveness Data and Information Set; MY: measurement year; **bolded text**: incentive measure; green: >= 50th NCQA national benchmark; red: < 50th NCQA national benchmark.

Table 13: ACLA HEDIS Measures Summary – MY 2020

Measure Status	ACLA
> 50th NCQA National Benchmark	30
< 50th NCQA National Benchmark	33
NCQA National Benchmark Unavailable	3
Total	66

ACLA: AmeriHealth Caritas Louisiana; HEDIS: Healthcare Effectiveness Data and Information Set; MY: measurement year.

VI. Validation of Quality of Care Surveys - CAHPS Member Experience Survey

Objectives

LDH requires quality assessment and improvement activities to ensure that Healthy Louisiana Medicaid MCO enrollees receive high-quality health care services (42 CFR Part 438). These activities include surveys of enrollees' experience with health care. LDH requires the MCOs to contract with an NCQA-certified HEDIS survey vendor to conduct annual CAHPS Health Plan Surveys. LDH contracted with IPRO to analyze the MCOs' Measurement Year (MY) 2020 survey data and report the results. All five Healthy Louisiana MCOs participated in the MY 2020 CAHPS Medicaid Health Plan Surveys.

Technical Methods of Data Collection and Analysis

LDH required the MCOs to administer the MY 2020 CAHPS Surveys according to NCQA HEDIS Specifications for Survey Measures. The standardized survey instruments administered in MY 2020 were the CAHPS 5.1H Adult Medicaid Health Plan Survey. Adult members from each MCO completed the surveys from February to May 2021.

CAHPS survey questions ask about experiences in a variety of areas. Results presented in this report include three global ratings: rating of health plan, rating of all health care, and rating of personal doctor, as well as individual survey responses for the following domains: Health Plan Ratings, Access to Care, Experience of Health Care Services, Preventive Care, and Health Status. Responses are summarized as achievement scores from 0 to 100.

To determine common strengths and opportunities for improvement across all MCOs, IPRO compared CAHPS MCO-specific and statewide averages for adults (**Table 14**), children without chronic conditions (**Table 15**), and children with chronic conditions (**Table 16**) to the national Medicaid benchmarks presented in the *Quality Compass* 2021. Measures performing at or above the 75th percentile were considered strengths; measures performing at the 50th percentile were considered average, while measures performing below the 50th percentile were identified as opportunities for improvement. IPRO used the member files to create detailed reports for the Louisiana Medicaid population.

Description of Data Obtained

IPRO received a copy of the final study report produced by each MCO-certified CAHPS vendor. In addition, deidentified member level files were received from each MCO.

Conclusions

IPRO's review of adult members surveyed (**Table 14**) found that ACLA ranked below the 50th percentile for Getting Care Quickly, Rating of Personal Doctor, and Rating of Specialist Seen Most Often. ACLA ranked at or above the 50th percentile for the Getting Needed Care, How Well Doctors Communicate, and Rating of Health Plan measures. ACLA ranked at or above the 75th percentile for Customer Service and Rating of All Health Care.

Table 14: CAHPS Performance – Adult Member

		Statewide (Healthy	2021 Quality Compass MY 2020 National Medicaid
CAHPS Measure	ACLA	Louisiana) Average	Mean
Getting Needed Care	84.88%	84.09%	83.58%
Getting Care Quickly	81.60%	80.78%	81.83%
How Well Doctors Communicate	92.74%	92.01%	92.17%
Customer Service	92.52%	90.10%	88.94%
Coordination of Care	88.35%	85.22%	N/A
Rating of All Health Care	81.59%	81.22%	77.63%
Rating of Personal Doctor	82.43%	84.21%	83.23%
Rating of Specialist Seen Most Often	83.17%	82.38%	83.56%
Rating of Health Plan	80.00%	81.40%	78.32%

^{*} Small sample size (less than 100).

CAHPS: Consumer Assessment of Healthcare Providers and Systems; ACLA: AmeriHealth Caritas Louisiana; MY: measurement year; green: ≥ 75th percentile; blue: 50th–74th percentile; red: < 50th percentile; N/A: national Medicaid benchmark data not available in Quality Compass.

IPRO's review of child members without chronic condition(s) (**Table 15**) found that ACLA ranked below the 50th percentile for the Rating of Health Plan measure. ACLA ranked at or above the 50th percentile for How Well Doctors Communicate, Customer Service, and Rating of Specialist Seen Most Often. ACLA ranked at or above the 75th percentile for Getting Needed Care, Getting Care Quickly, Rating of All Health Care, and Rating of Personal Doctor. Small sample sizes were identified for ACLA's Customer Service, and Rating of Specialist Seen Most Often measures.

Table 15: CAHPS Performance – Child Member (without chronic conditions)

CAHPS Measure	ACLA	Statewide (Healthy Louisiana) Average	2021 Quality Compass MY 2020 National Medicaid Mean
Getting Needed Care	89.28%	87.86%	85.65%
Getting Care Quickly	90.84%	89.76%	86.90%
How Well Doctors Communicate	95.45%	96.24%	94.36%
Customer Service	90.39%*	89.68%	88.32%
Coordination of Care	75.34%*	85.82%	N/A
Rating of All Health Care	92.68%	92.70%	88.91%
Rating of Personal Doctor	93.16%	92.86%	90.53%
Rating of Specialist Seen Most Often	88.89%*	89.69%	87.42%
Rating of Health Plan	85.40%	87.70%	86.63%

^{*} Small sample size (less than 100).

CAHPS: Consumer Assessment of Healthcare Providers and Systems; ACLA: AmeriHealth Caritas Louisiana; MY: measurement year; green: ≥ 75th percentile; blue: 50th–74th percentile; red: < 50th percentile; N/A: national Medicaid benchmark data not available in Quality Compass.

IPRO's review of child members with chronic condition(s) (**Table 16**) found that ACLA ranked below the 50th percentile for How Well Doctors Communicate. ACLA ranked at or above the 50th percentile for Getting Needed Care, Rating of All Health Care, and Rating of Health Plan. ACLA ranked at or above the 75th percentile

for Getting Care Quickly, Customer Service, Rating of Personal Doctor, and Rating of Specialist Seen Most Often. Small sample sizes were identified for ACLA's Customer Service, and Rating of Specialist Seen Most Often measures.

Table 16: CAHPS Performance – Child Member with Chronic Condition(s)

CAHPS Measure	ACLA	Statewide (Healthy Louisiana) Average	2021 Quality Compass MY 2020 National Medicaid Mean
Getting Needed Care	89.88%	88.94%	87.47%
Getting Care Quickly	93.11%	91.78%	90.83%
How Well Doctors Communicate	94.86%	95.57%	94.62%
Customer Service	94.44%*	92.35%	91.21%
Coordination of Care	73.66%*	76.37%	N/A
Rating of All Health Care	89.44%	90.76%	87.76%
Rating of Personal Doctor	91.46%	91.77%	89.52%
Rating of Specialist Seen Most Often	92.54%*	88.75%	87.51%
Rating of Health Plan	86.49%	85.63%	83.88%

^{*} Small sample size (less than 100).

CAHPS: Consumer Assessment of Healthcare Providers and Systems; ACLA: AmeriHealth Caritas Louisiana; MY: measurement year; green: ≥ 75th percentile; blue: 50th–74th percentile; red: < 50th percentile; N/A: national Medicaid benchmark data not available in Quality Compass.

Table 17–Table 19 show trends in ACLA's CAHPS measure performance between 2018 and 2021 and the Quality Compass national benchmark met/exceeded in 2021.

Table 17: ACLA Adult CAHPS 5.0H – 2018–2021 and National Benchmark Met/Exceeded in 2021

CAHPS Measure ¹	CAHPS 2018	CAHPS 2019	CAHPS 2020	CAHPS 2021	Quality Compass 2021 National – All LOBs Medicaid Benchmark Met/Exceeded ²
Getting Needed Care	79.59%	82.77%	81.37%	84.88%	50th
Getting Care Quickly	80.36%	85.73%	78.53%	81.60%	33.33rd
How Well Doctors Communicate	92.19%	92.91%	91.58%	92.74%	50th
Customer Service	90.87%	92.79%	90.98%	92.52%	90th
Coordination of Care	84.31%	82.73%	Small sample	88.35%	N/A
Rating of All Health Care	79.62%	72.14%	77.35%	81.59%	75th
Rating of Personal Doctor	80.54%	83.08%	83.33%	82.43%	33.33rd
Rating of Specialist	83.80%	84.95%	87.13%	83.17%	33.33rd
Rating of Health Plan	75.86%	79.19%	78.30%	80.00%	50th

¹For "Rating of" measures, Medicaid rates are based on ratings of 8, 9, and 10; for measures that call for respondents to answer with "Always," "Usually," "Sometimes," or "Never," the Medicaid rate is based on responses of "Always" or "Usually."

ACLA: AmeriHealth Caritas Louisiana; CAHPS: Consumer Assessment of Healthcare Providers and Systems; LOBs: lines of business; PPOs: preferred provider organizations; EPOs: exclusive provider organizations; Small sample: sample size less than 100; N/A: not available.

² Benchmark excludes PPOs and EPOs.

Table 18: ACLA Child CAHPS 5.0H General Population – 2018–2021

CAHPS Measure ¹	CAHPS 2018	CAHPS 2019	CAHPS 2020	CAHPS 2021	Quality Compass 2021 National – All LOBs Medicaid Benchmark Met/Exceeded ²
Getting Needed Care	93.26%	87.93%	86.71%	89.28%	75th
Getting Care Quickly	92.60%	91.54%	91.25%	90.84%	75th
How Well Doctors Communicate	95.06%	94.18%	94.17%	95.45%	50th
Customer Service	92.10%	95.02%	Small sample	Small sample	N/A
Coordination of Care	89.29%	78.57%	Small sample	Small sample	N/A
Rating of All Health Care	87.61%	87.21%	90.21%	92.68%	90th
Rating of Personal Doctor	88.40%	91.58%	92.79%	93.16%	75th
Rating of Specialist	92.77%	91.04%	Small sample	Small sample	N/A
Rating of Health Plan	92.76%	88.89%	89.09%	85.40%	33.33rd

¹For "Rating of" measures, Medicaid rates are based on ratings of 8, 9, and 10; for measures that call for respondents to answer with "Always," "Usually," "Sometimes," or "Never," the Medicaid rate is based on responses of "Always" or "Usually."

ACLA: AmeriHealth Caritas Louisiana; CAHPS: Consumer Assessment of Healthcare Providers and Systems; LOBs: lines of business; PPOs: preferred provider organizations; EPOs: exclusive provider organizations; Small sample: sample size less than 100; N/A: not available.

Table 19: ACLA Child CAHPS 5.0H CCC Population – 2018–2021

CAHPS Measure ¹	CAHPS 2018	CAHPS 2019	CAHPS 2020	CAHPS 2021	Quality Compass 2021 National – All LOBs Medicaid Benchmark Met/Exceeded ²
Getting Needed Care	90.19%	89.11%	88.88%	89.88%	66.67th
Getting Care Quickly	91.99%	96.31%	92.06%	93.11%	75th
How Well Doctors Communicate	94.23%	93.64%	95.62%	94.86%	33.33rd
Customer Service	91.54%	90.59%	Small sample	Small sample	N/A
Coordination of Care	79.82%	73.65%	Small sample	Small sample	N/A
Rating of All Health Care	87.76%	86.24%	93.03%	89.44%	66.67th
Rating of Personal Doctor	90.61%	87.45%	94.17%	91.46%	75th
Rating of Specialist	89.66%	84.38%	Small sample	Small sample	N/A
Rating of Health Plan	87.58%	86.22%	87.97%	86.49%	66.67th

¹For "Rating of" measures, Medicaid rates are based on ratings of 8, 9, and 10; for measures that call for respondents to answer with "Always," "Usually," "Sometimes," or "Never," the Medicaid rate is based on responses of "Always" or "Usually.

CAHPS: Consumer Assessment of Healthcare Providers and Systems; LOBs: lines of business; PPOs: preferred provider organizations; EPOs: exclusive provider organizations; Small sample: sample size less than 100; N/A: not available.

² Benchmark excludes PPOs and EPOs.

² Benchmark excludes PPOs and EPOs.

VII. Validation of Network Adequacy

General Network Access Requirements

In the absence of a CMS protocol for 42 CFR § 438.358 Activities related to external quality review (b)(1)(iv), IPRO assessed MCO compliance with the standards of 42 CFR § 438.358 Network adequacy standards and Section 7.0 of the state's Medicaid Services Contract.

Per section 7.1.1 the Contractor shall ensure that members have access to providers within reasonable time (or distance) parameters. The MCOs are required to maintain and monitor a network of appropriate providers that is supported by written network provider agreements and that is sufficient to provide adequate access to all services covered the contract for all members, including those with limited English proficiency or physical or mental disabilities.

Contractor shall also provide available, accessible and adequate numbers of institutional facilities, service locations, service sites, and professional personnel for the provision of services, including all specialized behavioral health emergency services, and shall take corrective action if there is failure to comply by any provider. At a minimum, this shall include:

GeoAccess Provider Network Accessibility

Objectives

Per section 7.3 of the state contract, the MCO shall comply with the maximum travel time and/or distance requirements as specified in the **Provider Network Companion Guide**. Requests for exceptions as a result of prevailing community standards must be submitted in writing to LDH for approval. Such requests should include data on the local provider population available to the non-Medicaid population. If LDH approves the exception, the MCO shall monitor member access to the specific provider type on an ongoing basis and provide the findings to LDH as part of its annual Network Provider Development Management Plan.

Table 20 displays the LDH-established access, distance, and time standards that were applicable in CY 2021 to PCPs, specialists and behavioral health providers.

Table 20: Louisiana Network Access Standards

Λ	00000	Requirements
-	11125	Keninenienis

Distance requirements for PCPs

Rural: Within 30 miles
Urban: Within 10 miles

Distance requirements for behavioral health providers and specialty providers

Laboratory and Radiology: Rural (within 30 miles), Urban (within 20 miles)

OB/GYN: Rural (within 30 miles), Urban (within 15 miles)

PCP: primary care provider; ob/gyn: obstetrician/gynecologist.

Technical Methods of Data Collection and Analysis

IPRO's evaluation was performed using the MCOs' quarterly GeoAccess reports, which document the geographic availability of network providers including PCPs, hospitals, pharmacies, and each specialty type listed in the **Provider Network Companion Guide**. IPRO compared each MCO's calculated distance analysis by specialty and by region to the LDH standards and a determination of whether the standard was met or not met was made.

Description of Data Obtained

The data and information obtained from the MCOs were related to provider counts, member geographical access, provider panel status, PCP-to-member ratios, distance analysis, and MCO narrative on improvement activities. These data were generally reported by region (rural, urban, and all). Additionally, each quarter, the MCOs are required to calculate and report the PCP-member ratio to LDH.

Conclusions

Table 21 displays ACLA's ratios for adult PCPs to members for CY 2018, CY 2019, and CY 2020. **Table 22** displays ACLA's ratios for pediatric PCPs to members for CY 2018, CY 2019, and CY 2020.

Table 21: ACLA Adult PCP-to-Member Ratios, MY 2018-MY 2020

Year	ACLA
2018	1.58%
2019	1.76%
2020	1.52%

ACLA: AmeriHealth Caritas Louisiana; PCP: primary care provider; MY: measurement year.

Table 22: ACLA Pediatric PCP-to-Member Ratios, MY 2018–MY 2020

Year	ACLA
2018	2.36%
2019	2.12%
2020	1.05%

ACLA: AmeriHealth Caritas Louisiana; PCP: primary care provider; MY: measurement year.

Table 23 displays ACLA's performance with regard to its adherence to GeoAccess urban and rural distance standards.

Table 23: ACLA Adherence to Provider Network Distance Standards, June 2021

Specialty	Region	Standard	ACLA
Physical health			
Acute Inpatient Hospitals	Urban	1 in 10 Miles	91.0%
	Rural	1 in 30 Miles	98.5%
Adult primary care	Urban	1 in 10 Miles	97.6%
	Rural	1 in 30 Miles	100.0%
Allergy/Immunology	Urban	1 in 60 Miles	94.0%
	Rural	1 in 60 Miles	82.4%
Cardiology	Urban	1 in 60 Miles	99.9%
	Rural	1 in 60 Miles	100.0%
Dermatology	Urban	1 in 60 Miles	90.8%
	Rural	1 in 60 Miles	79.2%
Endocrinology and	Urban	1 in 60 Miles	95.2%
Metabolism	Rural	1 in 60 Miles	88.9%
FQHCs	Urban	1 in 10 Miles	87.4%
	Rural	1 in 30 Miles	99.8%
Gastroenterology	Urban	1 in 60 Miles	99.9%
	Rural	1 in 60 Miles	100.0%

Specialty	Region	Standard	ACLA
Hematology/Oncology	Urban	1 in 60 Miles	99.9%
	Rural	1 in 60 Miles	96.1%
Hemodialysis Center	Urban	1 in 10 Miles	91.4%
	Rural	1 in 30 Miles	98.3%
Laboratory	Urban	1 in 20 Miles	98.5%
	Rural	1 in 30 Miles	99.9%
Nephrology	Urban	1 in 60 Miles	100.0%
	Rural	1 in 60 Miles	99.4%
Neurology	Urban	1 in 60 Miles	99.9%
	Rural	1 in 60 Miles	100.0%
Ob/gyn	Urban	1 in 15 Miles	94.9%
	Rural	1 in 30 Miles	95.0%
Ophthalmology	Urban	1 in 60 Miles	99.9%
	Rural	1 in 60 Miles	100.0%
Orthopedics	Urban	1 in 60 Miles	100.0%
	Rural	1 in 60 Miles	100.0%
Otorhinolaryngology/	Urban	1 in 60 Miles	99.9%
Otolaryngology	Rural	1 in 60 Miles	99.9%
Pediatrics	Urban	1 in 10 Miles	92.0%
	Rural	1 in 30 Miles	99.1%
Pharmacy	Urban	1 in 10 Miles	97.9%
	Rural	1 in 30 Miles	100.0%
Radiology	Urban	1 in 10 Miles	99.0%
-	Rural	1 in 30 Miles	98.6%
RHCs	Urban	1 in 10 Miles	24.4%
	Rural	1 in 30 Miles	100.0%
Urology	Urban	1 in 60 Miles	99.9%
	Rural	1 in 60 Miles	99.7%

ACLA: AmeriHealth Caritas Louisiana; FQHC: federally qualified health center; ob/gyn: obstetrics/gynecology; RHC: regional health center; gray: rate unavailable; green: MCO performance with GeoAccess standard of 100%; red: MCO performance less than 100%.

Provider Appointment Availability

Objectives

Minimum appointment availability standards have been established by LDH to ensure that members' needs are sufficiently met. LDH monitors the MCO's compliance with these standards through regular reporting as shown in Louisiana's **Provider Network Companion Guide**. The MCO ensures that appointments with qualified providers are on a timely basis, as follows:

- Emergent or emergency visits immediately upon presentation at the service delivery site. Emergent, crisis or emergency behavioral health services must be available at all times and an appointment shall be arranged within one (1) hour of request;
- Urgent Care within twenty-four (24) hours. Provisions must be available for obtaining urgent care, including behavioral health care, 24 hours per day, 7 days per week. Urgent care may be provided directly by the PCP or directed by the MCO through other arrangements. An appointment shall be arranged within forty-eight (48) hours of request;
- Non-urgent sick care within 72 hours or sooner if medical condition(s) deteriorates into an urgent or emergency condition;
- Routine, non-urgent, or preventative care visits within 6 weeks. For behavioral healthcare, routine, non-urgent appointments shall be arranged within fourteen (14) days of referral;

- Specialty care consultation within 1 month of referral or as clinically indicated;
- Lab and X-ray services (usual and customary) not to exceed three weeks for regular appointments and 48 hours for urgent care or as clinically indicated; and
- Maternity Care

Initial appointment for prenatal visits for newly enrolled pregnant women shall meet the following timetables from the postmark date the MCO mails the member's welcome packet for members whose basis of eligibility at the time of enrollment in the MCO is pregnancy. The timeframes below apply for existing member or new members whose basis of eligibility is something other than pregnancy from the date the MCO or their subcontracted provider becomes aware of the pregnancy.

- Within their first trimester within 14 days;
- Within the second trimester within 7 days;
- Within their third trimester within 3 days;
- High-risk pregnancies within 3 days of identification of high risk by the MCO or maternity care provider, or immediately if an emergency exists;
- Follow-up to ED visits in accordance with ED attending provider discharge instructions.
- In-office waiting time for scheduled appointments should not routinely exceed 45 minutes, including time in the waiting room and examining room.
- If a provider is delayed, patients shall be notified immediately. If the wait is anticipated to be more than 90 minutes, the patient shall be offered a new appointment.
- Walk-in patients with non-urgent needs should be seen if possible or scheduled for an appointment consistent with written scheduling procedures.
- Direct contact with a qualified clinical staff person must be available through a toll-free telephone number at all times.

Technical Methods of Data Collection and Analysis

IPRO's evaluation was performed using the MCOs' network data, provider directories, and policies and procedures submitted to LDH by the MCOs. Relevant information collected by IPRO during the Compliance Review was also utilized during this validation activity and incorporated into this report when applicable.

Description of Data Obtained

In late December 2020, each MCO electronically submitted their provider network data that are used to populate their web directory to IPRO. To conduct the survey, IPRO selected providers for each of the state's five MCOs.

The project comprised two types of calls and four provider types. Calls were made for routine appointments and non-urgent appointments. The four provider types were endocrinologists, dermatologists, neurologists, and orthopedic surgeons.

A "secret shopper" methodology was used to conduct the phone call survey. Surveyors were instructed to role-play as Medicaid managed care (MMC) members seeking care. Using scripted scenarios with clinical indicators that were developed by IPRO and approved by LDH, surveyors attempted to get appointments for care. Calls for the project were conducted between late February 2021 and April 2021.

Conclusions

Table 24 shows the results of the secret shopper calls for ACLA by appointment type.

Table 24: Appointment Availability for Network Providers, First Half of 2021

Appointment Type	ACLA
Routine ¹ Cardiologist	
# of providers surveyed	28
# of appointments made	12
Compliance Rate	42.9%
Routine ¹ ENT	
# of providers surveyed	22
# of appointments made	9
Compliance Rate	40.9%
Non-Urgent ² Cardiologist	
# of providers surveyed	23
# of appointments made	2
Compliance Rate	8.7%
Non-Urgent ² ENT	
# of providers surveyed	20
# of appointments made	2
Compliance Rate	10.0%

¹ Appointment standard for routine appointments is within 6 weeks.

ACLA: AmeriHealth Caritas Louisiana; ENT: ear, nose, and throat.

Recommendation

IPRO recommends that LDH work with ACLA to increase contact and appointment rates for cardiologists and ENTs.

² Appointment standard for non-urgent appointments is within 72 hours.

VIII. MCO Quality Ratings

Objectives

As part of its contract with the LDH, IPRO is responsible for developing a report card to evaluate the performance of the five Healthy Louisiana MCOs. The health plan quality rating system (QRS) is designed to increase health plans' transparency and accountability for the quality of services they provide their members. Consumers use these scorecards to help them choose a health plan. Many states use ratings for plan oversight and to make contracting decisions. Currently there is no CMS protocol for the Quality Rating Scorecard. States must create their own methodology until that time that CMS releases protocols.

Technical Methods of Data Collection and Analysis

IPRO's approach to the QRS for Report Year 2021, developed in consultation with NCQA, was as follows:

- Based on the overall categories and measures identified by NCQA and LDH as those included in both the prior year 2020 LA QRS Scorecard and the NCQA 2021 Measures List [excluding retired measures Adult BMI Assessment (ABA) and Medication Management for People with Asthma (MMA)], IPRO created a spreadsheet with (a) the selected HEDIS/CAHPS measures, (b) their NCQA 2021 weighting, (c) MCO RY 2021 HEDIS/CAHPS results (MY 2020), and (d) HEDIS RY 2020 Medicaid NCQA Quality Compass (QC) Percentiles (MY 2019).
- 2. IPRO scored individual CAHPS and HEDIS measures by comparing each unweighted MCO RY 2021 measure rate to each corresponding unweighted QC RY 2020 measure percentile rates (National All Lines of Business):
 - A plan that is ≥ 90th Percentile: Score = 5
 - A plan that is ≥ 66.67th and < 90th Percentiles: Score = 4
 - A plan that is ≥ 33.33rd and < 66.67th Percentiles: Score = 3
 - A plan that is ≥ 10th and < 33.33rd Percentiles: Score = 2
 - A plan that is < 10th Percentile: Score = 1
- 3. IPRO applied the NCQA RY 2021 measure weights to each MCO RY 2021 measure score (i.e., weight X score).
- 4. IPRO aggregated individual measure rates into QRS categories (e.g., Getting Care, Satisfaction with Plan Physicians, Satisfaction with Plan Services, Children and Adolescent Well-Care, Women's Reproductive Health, Cancer Screening, Other Preventive Services, Treatment, Behavioral Health, Other Treatment Measures, and Overall Rating), as follows: (Sum of weighted scores) ÷ (Sum of weights); then apply the NCQA rounding rules (NCQA 2021 Health Plan Ratings Methodology, p. 3). A .5 bonus is added to the overall MCO rating for accreditation.
- 5. IPRO assigned QRS 2021 star ratings by assigning the same number of stars to match the rounded scores (0.0, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0).
- Exception in response to COVID-19's impact to Health Plans: If QRS 2021 star rating < QRS 2020 star rating, then QRS 2020 star rating will be reported.

For prior Report Year (RY) 2020, LDH utilized the NCQA 2020 Report Card, which compared MCO MY 2019 rates to *Quality Compass* MY 2019 rates. This year, LDH has requested that IPRO develop a QRS Scorecard for RY 2021 that uses the same methodology used by NCQA, with the following exception: The Healthy Louisiana 2021 QRS Scorecard is required prior to the release of the 2021 Medicaid *Quality Compass* Percentiles for MY 2020 (release date: September 24, 2021). Therefore, IPRO's methodology will differ from NCQA's in that MCO 2020 MY rates will be compared to *Quality Compass* 2019 MY rates. To address the potential for temporal confounding due comparisons between MCO rates measured during the COVID-19 pandemic (MY 2020) and *Quality Compass* rates measured pre-COVID (MY 2019), last year's QRS ratings will be used for those MCO QRS items with current 2021 scores lower than scores from last year. In response to LDH's request, IPRO met with NCQA to ensure that application of the scoring methodology is consistent with that used by NCQA.

Description of Data Obtained

The MY 2020 star rating results for ACLA are displayed in Figure 1.

Conclusions

Figure 1 shows that ACLA ranked above average in overall rating, satisfaction with plan physicians and satisfaction with plan services with four stars each.

ACLA scored low (two stars) in treatment for asthma, diabetes, and mental/behavioral health, as well as overall treatment.

HEALTH PLAN REPORT CARD



Issued 08/2021

The ratings below compare the performance of Louisiana's Medicaid health plans. This report card shows the results of care in the areas of Consumer Satisfaction, Prevention and Treatment, and can aid you and your family when deciding on a health plan.

Performance Key	Lowest 🖈	Low	Average	High	Highest
	Aetna Better Health of Louisiana	AmeriHealth Caritas Louisiana	Healthy Blue	Louisiana Healthcare Connections	UnitedHealthcare Community Plan of Louisiana
Overall Rating	***	***	****	***	****
CONSUMER SATISFACTION	ON				
Overall Consumer Satisfaction	****	***	***	****	****
Getting Care: How easily and quickly did members get appointments, preventive care, tests, and treatments?	***	****	***	***	N/A
Satisfaction with plan physicians: How happy are members with their doctors and other healthcare providers?	****	***	****	****	****
Satisfaction with plan services: How happy are members with their plan's customer service and how benefits are handled?	***	***	****	****	****
PREVENTION					
Overall Prevention	**	***	***	***	***
Children/ adolescent well-care: Do children and adolescents receive the care they need to stay healthy, such as vaccines, well-child visits, and dental visits?	**	***	***	***	***
Women's health: Do women receive important screenings for health problems? Do women receive care before and after their babies are born?	***	***	***	**	***

continued on next page...

Cancer screening: Do members receive important cancer screenings?	**	***	**	***	**
TREATMENT					
Overall Treatment	**	**	***	**	***
Asthma: Do people with asthma get the services and treatments they need?	**	**	****	****	****
Diabetes: Do people with diabetes get the services/treatments they need?	**	**	**	**	***
Heart disease: Do people with heart disease get the services/treatments they need?	**	***	**	**	***
Mental and behavioral health: Do people with mental health issues get the services/treatments they need?	**	**	**	**	**

The source of data contained herein is based on the categories and measures identified by National Committee for Quality Assurance (NCQA) and LDH as those included in both the prior year 2020 Louisiana Quality Rating System (QRS) Scorecard and the NCQA 2021 Measures List. NCQA reviewed and provided feedback to IPRO on the methodology used. Any analysis, interpretation or conclusion based on the data is solely that of IPRO and NCQA. These materials may not be modified by anyone other than IPRO and NCQA. Anyone desiring to use or reproduce the materials must obtain approval from LDH.

IX. EQRO's Assessment of MCO Responses to the Previous EQR Recommendations

Title 42 CFR § 438.364 External quality review results (a)(6) require each annual technical report include "an assessment of the degree to which each MCO, PIHP, PAHP, or PCCM entity has effectively addressed the recommendations for QI made by the EQRO during the previous year's EQR." **Table 25** displays ACLA's responses to the recommendations for QI made by IPRO during the previous EQR, as well as IPRO's assessment of these responses.

Table 25 shows a description of the assessment levels used by IPRO to evaluate ACLA's response.

Table 25: MCO Response to Recommendation Assessment Levels

Assessment Determinations	Definitions
Addressed	MCO's QI response resulted in demonstrated improvement.
Partially Addressed	MCO's QI response was appropriate; however, improvement is still needed.
Remains an Opportunity for	MCO's QI response did not address the recommendation; improvement was not
Improvement	observed, or performance declined.

MCO: managed care organization; QI: quality improvement.

ACLA Response to Previous EQR Recommendations

Title 42 CFR § 438.364 External quality review results (a)(6) require each annual technical report include "an assessment of the degree to which each MCO, PIHP, PAHP, or PCCM entity has effectively addressed the recommendations for QI made by the EQRO during the previous year's EQR." **Table 26** displays ACLA's responses to the recommendations for QI made by IPRO during the previous EQR, as well as IPRO's assessment of these responses.

Table 26: ACLA Response to Previous EQR Recommendations

Recommendation for ACLA	ACLA Response/Actions Taken	IPRO Assessment of MCO Response ¹
For the Improving Rates	Performance Indicator and Intervention Tracking Measure data is	Addressed
for (1) Initiation and	validated and monitored as appropriate through trending, PDSA	
Engagement of Alcohol	cycles, run charts, and other QI tools to analyze impact and	
and Other Drug Abuse or	effectiveness. To assure measures are calculated correctly,	
Dependence Treatment	AmeriHealth Caritas Louisiana has implemented a second level data	
(IET) and (2) Follow-Up	review by the Quality Team Lead to validate calculations.	
After Emergency		
Department Visit for		
Alcohol and Other Drug		
Abuse or Dependence PIP,		
it was found that the		
results must be		
interpreted with some		
caution due data		
correction required for		
one of the performance		
indicators. Also, for the		
Improve Screening for		
Chronic Hepatitis C Virus		
(HCV) and Pharmaceutical		
Treatment Initiation PIP, it		
was found that the results		

Barrier de la Contraction de l		IPRO Assessment
Recommendation for ACLA	ACLA Response/Actions Taken	of MCO Response ¹
must be interpreted with some caution due discrepancies in the denominator of a performance indicator.		
The MCO should devote adequate resources and staff to future PIPs to correctly calculate measures and assure the		
PIP's validity. Seventeen of 30 HEDIS measures fell below the 50th percentile; the MCO should continue to evaluate the effectiveness of their current interventions. Low-performing HEDIS measures have shown little improvement from prior year with the exception of: • Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents - Counseling for Physical Activity • Access to other services • Prenatal care • Postpartum care The MCO should develop specific interventions to address the worst performing HEDIS measures: • Antidepressant Medication Management - Acute Phase (< 25th percentile) • Antidepressant Medication Management -	AmeriHealth Caritas Louisiana is committed to improving the quality of care and health outcomes for our members. The plan strives to exceed the NCQA Quality Compass 50th percentile in HEDIS metrics and performs month-over-month trending and benchmarking against Quality Compass to drive root cause analyses for successes and opportunities for improvement. AmeriHealth Caritas Louisiana's biweekly Health Outcomes Workgroup consists of our leadership team that includes our CEO, CMO, COO, Quality Director, Population Health Director, Member Services Director, and Provider Supports Director, among other key topic participants. The Health Outcomes Workgroup provides a forum to review interim HEDIS rates, trends, and intervention effectiveness. Interdepartmental workgroups are held quarterly with department subject matter experts to communicate barriers, modify/develop interventions, and evaluate intervention effectiveness. Priority HEDIS metrics are shared with the plan's Quality of Clinical Care Committee and the Quality Assessment and Performance Improvement Committee for discussion and feedback. Additionally, AmeriHealth Caritas Louisiana conducts an annual evaluation of the QM/QI program. The following activities were continued, enhanced, initiated, or are planned for initiation to address low performing HEDIS metrics: Perform monthly HEDIS data trending and analysis. Perform segmentation analysis by diagnosis, age, race, ethnicity, parish and provider/ facility access and availability. Analyze utilization patterns to detect potential areas to improve overutilization and underutilization rates and barriers to receiving the right care. Continued and enhanced Quality Improvement Activities on all priority measures. Developed and implemented a comprehensive provider support strategy to include training, technology, data and alternative payment methods. Performed targeted provider education through a multidisciplinary team approach. Provided provider care gap reports and performance report cards.	Partially addressed

Recommendation for		IPRO Assessment of MCO
		Response ¹
Recommendation for ACLA (< 25th percentile) Asthma Medication Ratio (5–64 Years) (< 25th percentile) Controlling High Blood Pressure (< 25th percentile) Adults' Access to Preventive/Ambulator y Services 65+ years (< 10th percentile) Ambulatory Care Emergency Department Visits/1,000 Member Months (> 90th percentile; a lower rate is desirable)	based practice guidelines and optimizing quality enhancement program payments. Promoted telemedicine services and billing Conduct member outreach via face to face encounters, texting campaigns, telephonic, mailings, social media and community events. Promote wellness and prevention by engaging and empowering members to seek preventive care, complete ageappropriate screenings, and make healthy choices. Offered a vigorous Case Management program to members, presenting interventions such as care coordination, medication education and reconciliations, transition of care, depression screening tools, and social determinants of health assessment. AmeriHealth Caritas Louisiana's Case Management Team is also prepared to begin an Asthma Navigation Program in 2022. Collaborate with the School Based Health Centers to promote well visits and immunizations. Partnered with the American Academy of Pediatrics (AAP) on the following: Improve the treatment and health outcomes of children with Attention Deficit Hyperactivity Disorder (ADHD). Back to the Office Campaign Partner with Capital Area United Way and Care South to execute and support a 2-month pilot program to provide fresh fruits and vegetables to identified members in definite communities with a diagnosis of obesity that may also have diabetes or hypertension. Partnered with Our Lady of the Lake for an Asthma Camp initiative wherein school-aged members with asthma diagnosis are invited to attend and gain tools for asthma management Equip members with tools, education, and care coordination to effectively self-manage chronic conditions. Offered a variety of community-focused activities such as virtual WHAM (Whole Health Action Management) classes, which included tips on healthy lifestyle changes, and communal baby showers at our Community Wellness Centers. ACLA has also partnered with LSU Agricultural Center to plan a robust Choose to Lose weight management class to begin, in-person, in 2022.	
	 Executed plan-wide quality activities and communications, including all-employee trainings. Offered member Care Card incentives for a variety of services, 	
	such as wellness care, certain preventive screenings, annual diabetic screenings, and some immunizations.	

Recommendation for		IPRO Assessment of MCO
ACLA	ACLA Response/Actions Taken	Response ¹
	 Partnered with Vheda Health to deliver a digital chronic disease management program for our high-risk member population enrolled in the Complex Case Management Program. Continued and enhanced the Make Every Calorie Count program, a weight-loss program designed to encourage lifestyle change. Membership includes an option of gym membership or home fitness plan. Implemented programs to outreach members for follow-up after emergency department visit for mental illness or alcohol and other drug abuse or dependence, or recent hospitalization for mental illness. The plan outreaches members via text messaging, member letters, and phone calls. 	Response
Nine (9) of 27 CAHPS measures fell below the 50th percentile; the MCO should continue to work to improve CAHPS scores that perform below the 50th percentile. The MCO should develop specific interventions to address the worst performing CAHPS measures: Adult population: Getting Care Quickly (< 25th percentile) How Well Doctors Communicate (< 25th percentile) Child General population: How Well Doctors Communicate (< 25th percentile)	AmeriHealth Caritas Louisiana consistently works to improve CAHPS scores for both the Adult and Children surveys by identifying opportunities where the Plan performs below the NCQA 50 th percentile. AmeriHealth Caritas Louisiana continued its CAHPS workgroup of multidisciplinary internal departments. Through this collaboration, we have addressed several priority CAHPS Work Plan items. We have improved our internal associates' CAHPS awareness through enterprise-wide presentations of general CAHPS information, specifics of the Adult and Children surveys, and a detailed breakdown of the Final Results Report. Further, we have presented a more comprehensive analysis to all member-facing associates and/or departments with an emphasis on CAHPS-centered initiatives, such as end-of-call scripting. In addition to increasing our associates' and members' awareness of CAHPS, we developed provider education/newsletters to be sent to all providers. Similar to our associate-directed CAHPS education goals, these provider newsletters were developed to provide a generalized overview of the Adult and Child CAHPS surveys, as well as a detailed breakdown of the provider-driven elements of the Final Results Report. AmeriHealth Caritas Louisiana provides numerous opportunities for enrollee and family member feedback to improve satisfaction and care. In addition to the CAHPS and behavioral health enrollee satisfaction surveys, AmeriHealth Caritas Louisiana uses pulse surveys that allow enrollees to respond by text and emojis regarding their experience after a provider visit. Additionally, the plan uses community outreach and engagement, the Enrollee Advisory Council, focus groups, technology (mobile app, texts, and social media), as well as complaints and grievances to assess ways to improve enrollee experience and inform strategies for program improvements. In an effort to boost CAHPS response rates, AmeriHealth Caritas Louisiana is implementing a head-of-household mailer to raise CAHPS awareness. Both the Adult and Child CAHPS sur	Partially addressed

Recommendation for		IPRO Assessment of MCO
ACLA	exceeded the 2019 National Quality Compass 50th Percentile for the Child CAHPS survey, and 4 of the 9 for the Adult survey. Lastly, NCQA Announcements regarding survey changes for 2020 CAHPS indicated the intent to shorten the HEDIS CAHPS surveys to reduce response burden for members. Due to this, Shared Decision Making was removed from the survey. Also for 2020 CAHPS, NCQA no longer produced General Population results for the CCC Population and no longer produced CCC results for the General Population. With these changes, there will no longer be an opportunity to measure effectiveness on our ongoing interventions regarding our lower scores for General Child Shared Decision Making and Child with CCC Shared	Response ¹
Compliance Monitoring Only 10 of 21 (48%) Provider Network requirements that were not fully compliant in the 2019 compliance review	Decision Making and Rating of Specialist. AmeriHealth Caritas Louisiana continues to outreach providers in areas of need to encourage providers to expand or add needed services. In addition, Account Executives outreach PCPs and large groups to expand services or open panels that may be closed due to meeting capacity. There are some rural parishes with very small populations, which	Partially addressed
were found to be fully compliant in the 2020 compliance review. The MCO should work with providers to meet their federal and	restricts the ability to recruit providers to those areas. In most of these areas, AmeriHealth Caritas Louisiana has worked with the existing providers to encourage partnerships and working relationships with larger health systems that are in close proximity. Account Executives are provided with network gap analysis reports,	
state Provider Network access requirements.	which are reviewed monthly, along with the Network Adequacy report to identify areas and provider types that do not meet Provider Network access requirements so that targeted provider visits and outreach can be conducted accordingly. Account Executives educate providers regarding alternate payment models to encourage participating providers to keep panels open and as a mechanism to recruit new providers.	

¹ IPRO assessments are as follows: **addressed**: MCO's quality improvement (QI) response resulted in demonstrated improvement; **partially addressed**: MCO's QI response was appropriate; however, improvement was not yet observed; **remains an opportunity for improvement**: MCO's QI response did not address the recommendation; improvement was not observed or performance declined. EQR: external quality review; ACLA: AmeriHealth Caritas Louisiana; MCO: managed care organization; PIP: performance improvement project; PDSA: plan-do-study-act; HEDIS: Healthcare Effectiveness Data and Information Set; NCQA: National Committee for Quality Assurance; CEO: chief executive officer, CMO: chief medical officer, COO: chief operating officer; QM: quality management; QI: quality improvement; LSU: Louisiana State University; CAHPS: Consumer Assessment of Healthcare Providers and Systems; CCC: children with chronic conditions; PCP: primary care provider.

X. MCO Strengths, Opportunities for Improvement, and EQR Recommendations

Table 27 highlights ACLA's performance strengths and opportunities for improvement, follow-up on prior EQRO recommendations, and this year's recommendations based on the aggregated results of SFY 2021 EQR activities as they relate to **quality, timeliness**, and **access**.

ACLA Strengths and Opportunities for Improvement, and EQR Recommendations

Table 27: ACLA Strengths and Opportunities for Improvement, and EQR Recommendations

EQR Activity	rengens and opportunities for improvement, and Eq.(need	Quality	Timeliness	Access
Strengths				
PIPs ¹ 1. Improving Rates for (1) Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment (IET) and (2) Follow-Up After Emergency Department Visit for Alcohol and Other Drug Abuse or Dependence	There were no validation findings which indicate that the credibility of the PIP results is at risk. The following performance indicators represent strengths because they showed improvement from baseline to final remeasurement of at least 3 percentage points: Indicator 5: Engagement of AOD Treatment: Total age groups, Opioid abuse or dependence diagnosis cohort Indicator 7: The percentage of emergency department (ED) visits for members 13 years of age and older with a principal diagnosis of alcohol or other drug (AOD) abuse or dependence who had a follow up visit for AOD within 30 days of the ED visit		x	x
2. Improve Screening for Chronic Hepatitis C Virus (HCV) and Pharmaceutical Treatment Initiation	 There were no validation findings which indicate that the credibility of the PIP results is at risk. The following performance indicators demonstrated improvement of at least 3 percentage points from baseline to final remeasurement: Performance Indicator 1a (Universal Screening) Performance Indicator 1b (Birth Cohort Screening) Performance Indicator 2a (Non-Birth Cohort/Risk Factor Screening- ever screened) Performance Indicator 3a (HCV Treatment Initiation-Overall) Performance Indicator 3b (HCV Treatment Initiation-Drug Users) Performance Indicator 3c (HCV Treatment Initiation-Persons with HIV) 			X
Compliance with Medicaid and CHIP Managed Care Regulations	ACLA demonstrated full compliance in 10 of 11 domains.	х		
Performance Measures	 In MY 2020, ACLA had 30 of 66 HEDIS measures equal or greater than 50th NCQA national benchmark. ACLA successfully reported HEDIS on time. ACLA was compliant with the IS standards. 	х		
Quality of Care Surveys – Member	In 2021, ACLA performed better than the national Medicaid average for All LOBs (excluding PPOs):	х	Х	Х

EQR Activity		Quality	Timeliness	Access
Experience	Adult CAHPS:			
'	Getting Needed Care			
	How Well Doctors Communicate			
	Customer Service			
	Rating of All Health Care			
	Rating of Health Plan			
	Children With Chronic Conditions (CCC) CAHPS:			
	Getting Needed Care			
	Getting Care Quickly			
	Rating of All Health Care			
	Rating of Personal Doctor			
	Rating of Health Plan			
	Child General (Non-CCC) CAHPS:			
	 Getting Needed Care 			
	Getting Care Quickly			
	How Well Doctors Communicate			
	 Rating of All Health Care 			
	 Rating of Personal Doctor 			
Network	None identified.			
Adequacy				
Quality Ratings	Overall Consumer Satisfaction (four out of five stars)			
	 Satisfaction with plan physicians 	X		
	 Satisfaction with plan services 			
NCQA	Accredited	.,		
Accreditation		Х		
Opportunities for				
Improvement				
PIPs ¹	The following performance indicators represent opportunities			
1. Improving Rates	for improvement because they did not show improvement			
for (1) Initiation	from baseline to final remeasurement of at least 3			
and Engagement	percentage points:			
of Alcohol and	Indicator 1: Initiation of AOD Treatment: Total age			
Other Drug Abuse	groups, Alcohol abuse or dependence diagnosis cohort			
or Dependence	Indicator 2: Initiation of AOD Treatment: Total age			
Treatment (IET)	groups, Opioid abuse or dependence diagnosis cohort			
and (2) Follow-Up	Indicator 3: Initiation of AOD Treatment: Total age			
After Emergency	groups, Total diagnosis cohort			
Department Visit	Indicator 4: Engagement of AOD Treatment: Total age			
for Alcohol and	groups, Alcohol abuse or dependence diagnosis cohort		v	v
Other Drug Abuse	Indicator 6: Engagement of AOD Treatment: Total age		Х	X
or Dependence	groups, Total diagnosis cohort			
	Indicator 8: The percentage of emergency department			
	(ED) visits for members 13 years of age and older with a			
	principal diagnosis of alcohol or other drug (AOD) abuse			
	or dependence who had a follow up visit for AOD within 7			
	days of the ED visit			
	There is an opportunity to derive updated barrier analysis			
	information by conducting focus groups with provider			
	organizations.			
	There is an opportunity to address geographic disparity			
	areas identified in the driver diagram by implementing			

EQR Activity		Quality	Timeliness	Access
	PIP interventions in those areas.			
	ITMs indicate that members with co-morbid serious			
	mental illness are more successfully outreached and			
	receiving follow-up compared to those with SUD. There is			
	an opportunity to add an intervention to improve			
	member receipt of psychosocial SUD treatment.			
2. Improve	The following performance indicators did not demonstrate			
Screening for	improvement of at least 3 percentage points from baseline to			
Chronic Hepatitis	final remeasurement:			
C Virus (HCV) and	Performance Indicator 2b (Non-Birth Cohort/Risk Factor			
Pharmaceutical	Screening- Annual Screening)			v
Treatment	There was an opportunity to conduct a systematic barrier			X
Initiation	analysis to identify susceptible subpopulations.			
	There was an opportunity to stratify performance			
	indicators by member characteristics such as geographic			
	area.			
Compliance with	Adequate Capacity and Service			
Medicaid and CHIP	 Finding: Distance and/or time requirements were not 			
Managed Care	met for urban and rural parishes.			
Regulations	 Finding: The MCO did not provide evidence that "the 	Х		X
	plan shall specifically assess the extent to which the			
	MCO's in-state network is sufficient to meet the			
	needs of this population."			
Performance	In MY 2020, ACLA had 4 of 66 HEDIS measures lower than			
Measures	10th NCQA national benchmark, and 12 of 66 HEDIS	Х	X	X
	measures between 10th and 25th NCQA national benchmark.			
Quality of Care	In 2021, ACLA performed below than the national Medicaid			
Surveys – Member	average for All LOBs (excluding PPOs):			
	Adult CAHPS:			
	 Getting Care Quickly 			
	 Rating of Personal Doctor 	х	X	Х
	 Rating of Specialist 		, A	^
	Children With Chronic Conditions (CCC) CAHPS:			
	 How Well Doctors Communicate 			
	Child General (Non-CCC) CAHPS:			
	Rating of Health Plan			
Network	ACLA adult PCP to member ratio dropped from 1.58% to			
Adequacy	1.52% from MY 2018 to MY 2020, its pediatric PCP to			
	member ratio dropped from 2.36% to 1.05% from MY 2018 to			X
	MY 2020. ACLA met 23% of the provider network distance			
	standards.			
Quality Ratings	Overall treatment (two stars)			
	o Asthma	X		
	o Diabetes			
Danama and Late	Mental health McOto Address Ovelite Timeliness and Assess	<u> </u>		
	to MCO to Address Quality, Timeliness, and Access	ı		
PIPs ¹	The MCO was advised to obtain direct member feedback			
1. Improving Rates	from Care Management outreach in response to poorly			
for (1) Initiation	performing ITMs.	X		X
and Engagement	It was found that the results must be interpreted with some			
of Alcohol and	caution due to data correction required for one of the			

Department Visit for Alcohol and Other Drug Abuse or Dependence 2. Improve Screening for Chronic Hepatitis C Virus (HCV) and Pharmaceutical Treatment Initiation For both PIPs, the MCO should devote adequate resources and sasure the PIP's validity. Compliance with Medicaid and CHIP Managed Care Regulations Regulations Performance None identified. None identified. None identified. Nine (9) of 27 CAHPS measures fell below the 50th percentile; the MCO should devole population: None identified work to surveys – Member None identified. The MCO should develop specific interventions to address the worst performing CAHPS measures: O Adult population: X X X X X X X	EQR Activity		Quality	Timeliness	Access
or Dependence Treatment (IET) and (2) Follow-Up After Emergency Department Visit for Alcohol and Other Drug Abuse or Dependence 2. Improve Screening for Chronic Hepatitis C Virus (HCV) and Pharmaceutical Treatment Initiation For both PIPs, the MCO should devote adequate resources and staff to future PIPs to correctly calculate measures and assure the PIP's validity. Compliance with Medicaid and CHIP Managed Care Regulations Adequate Capacity and Service The MCO should improve access to PCPs for their urban members. The MCO should assess the extent to which their in- state network is sufficient to meet the needs of individuals with a dual diagnosis of behavioral health and developmental disabilities. None identified. The MCO should continue to work to improve CAHPS scores that perform below the 50th percentile; The MCO should develop specific interventions to address the worst performing CAHPS measures: Adult population: X X X X Y X X Y X X X X X X X X X X		performance indicators.			
Treatment (IET) and (2) Follow-Up After Emergency Department Visit for Alcohol and Other Drug Abuse or Dependence 2. Improve Screening for Chronic Hepatitis C Virus (HCV) and Pharmaceutical Treatment Initiation For both PIPs, the MCO should devote adequate resources and staff to future PIPs to correctly calculate measures and assure the PIP's validity. Compliance with Medicaid and CHIP Managed Care Regulations Regulations Performance Performance None identified. None identified. Nine (9) of 27 CAHPS measures fell below the 50th percentile; the MCO should develop specific interventions to address the worst performing CAHPS measures: O Adult population: X X X X X X X X	~				
and (2) Follow-Up After Emergency Department Visit for Alcohol and Other Drug Abuse or Dependence 2. Improve Screening for Chronic Hepatitis C Virus (HCV) and Pharmaceutical Treatment Initiation For both PIPs, the MCO should devote adequate resources and staff to future PIPs to correctly calculate measures and assure the PIP's validity. Adequate Capacity and Service Medicaid and CHIP Managed Care Regulations O The MCO should assess the extent to which their in- state network is sufficient to meet the needs of individuals with a dual diagnosis of behavioral health and developmental disabilities. Performance Measures Oncient Fig. 1. In the MCO should continue to work to improve CAHPS scores that perform below the 50th percentile; the MCO should develop specific interventions to address the worst performing CAHPS measures: O Adult population: X X X X Adequate Capacity and Service O The MCO should improve access to PCPs for their urban members. A X X X X X A	•				
After Emergency Department Visit for Alcohol and Other Drug Abuse or Dependence 2. Improve Screening for Chronic Hepatitis C Virus (HCV) and Pharmaceutical Treatment Initiation For both PIPs, the MCO should devote adequate resources and staff to future PIPs to correctly calculate measures and assure the PIP's validity. Compliance with Medicaid and CHIP Managed Care Regulations Adequate Capacity and Service The MCO should improve access to PCPs for their urban members. The MCO should assess the extent to which their in- state network is sufficient to meet the needs of individuals with a dual diagnosis of behavioral health and developmental disabilities. None identified. None identified. None identified. Nine (9) of 27 CAHPS measures fell below the 50th percentile; the MCO should develop specific interventions to address the worst performing CAHPS measures: Adult population: X X X X X X X X X X X X X	and (2) Follow-Up				
Department Visit for Alcohol and Other Drug Abuse or Dependence 2. Improve Screening for Chronic Hepatitis C Virus (HCV) and Pharmaceutical Treatment Initiation For both PIPs, the MCO should devote adequate resources and staff to future PIPs to correctly calculate measures and assure the PIP's validity. Compliance with Medicaid and CHIP Managed Care Regulations Regulations Performance None identified. None identified. None identified. Nine (9) of 27 CAHPS measures fell below the 50th percentile; the MCO should devole performing CAHPS measures: O Adult population: X X X X X X X X X X X X X X X X X X X X X X Adequate Capacity and Service O The MCO should improve access to PCPs for their urban members. O The MCO should assess the extent to which their instate network is sufficient to meet the needs of individuals with a dual diagnosis of behavioral health and developmental disabilities. Performance Measures Quality of Care Surveys – Member Nine (9) of 27 CAHPS measures fell below the 50th percentile; the MCO should continue to work to improve CAHPS scores that perform below the 50th percentile. • The MCO should develop specific interventions to address the worst performing CAHPS measures: O Adult population:	After Emergency				
for Alcohol and Other Drug Abuse or Dependence 2. Improve Screening for Chronic Hepatitis C Virus (HCV) and Pharmaceutical Treatment Initiation For both PIPs, the MCO should devote adequate resources and staff to future PIPs to correctly calculate measures and assure the PIP's validity. Compliance with Medicaid and CHIP Managed Care Regulations Regulations Performance Measures Quality of Care Surveys – Member It was found that the results must be interpreted with some caution due discrepancies in the denominator of a performance with Medicaid and CHIP Managed Care Regulations None identified. None identified. None identified. The MCO should ontinue to work to improve CAHPS scores that perform below the 50th percentile; the MCO should devote adequate resources and staff to future PIPs to correctly calculate measures and assure the PIP's validity. X X X X X X X X X X X X X X X X X	Department Visit				
or Dependence 2. Improve Screening for caution due discrepancies in the denominator of a performance indicator. Virus (HCV) and Pharmaceutical Treatment Initiation For both PIPs, the MCO should devote adequate resources and staff to future PIPs to correctly calculate measures and assure the PIP's validity. Compliance with Medicaid and CHIP Managed Care Regulations Regulations Performance None identified. None identified. Performance Surveys – Member The MCO should develop specific interventions to address the worst performing CAHPS measures: Adult population: Ax	for Alcohol and				
or Dependence 2. Improve Screening for caution due discrepancies in the denominator of a performance indicator. Virus (HCV) and Pharmaceutical Treatment Initiation For both PIPs, the MCO should devote adequate resources and staff to future PIPs to correctly calculate measures and assure the PIP's validity. Compliance with Medicaid and CHIP Managed Care Regulations Regulations Performance None identified. None identified. Performance Surveys – Member The MCO should develop specific interventions to address the worst performing CAHPS measures: Adult population: Ax	Other Drug Abuse				
Screening for Chronic Hepatitis C Virus (HCV) and Pharmaceutical Treatment Initiation For both PIPs, the MCO should devote adequate resources and staff to future PIPs to correctly calculate measures and assure the PIP's validity. Compliance with Medicaid and CHIP Managed Care Regulations The MCO should improve access to PCPs for their urban members. The MCO should assess the extent to which their in- state network is sufficient to meet the needs of individuals with a dual diagnosis of behavioral health and developmental disabilities. Performance Measures Quality of Care Surveys – Member Nine (9) of 27 CAHPS measures fell below the 50th percentile; the MCO should develop specific interventions to address the worst performing CAHPS measures: Aut X X X X X X X X X	or Dependence				
Screening for Chronic Hepatitis C Virus (HCV) and Pharmaceutical Treatment Initiation For both PIPs, the MCO should devote adequate resources and staff to future PIPs to correctly calculate measures and assure the PIP's validity. Compliance with Medicaid and CHIP Managed Care Regulations The MCO should improve access to PCPs for their urban members. The MCO should assess the extent to which their in- state network is sufficient to meet the needs of individuals with a dual diagnosis of behavioral health and developmental disabilities. Performance Measures Quality of Care Surveys – Member Nine (9) of 27 CAHPS measures fell below the 50th percentile; the MCO should develop specific interventions to address the worst performing CAHPS measures: Aut X X X X X X X X X	2. Improve	It was found that the results must be interpreted with some			
Chronic Hepatitis C Virus (HCV) and Pharmaceutical Treatment Initiation For both PIPs, the MCO should devote adequate resources and staff to future PIPs to correctly calculate measures and assure the PIP's validity. Compliance with Medicaid and CHIP Managed Care Regulations The MCO should improve access to PCPs for their urban members. The MCO should assess the extent to which their instate network is sufficient to meet the needs of individuals with a dual diagnosis of behavioral health and developmental disabilities. Performance Measures Quality of Care Surveys – Member Nine (9) of 27 CAHPS measures fell below the 50th percentile; the MCO should continue to work to improve CAHPS scores that perform below the 50th percentile; The MCO should develop specific interventions to address the worst performing CAHPS measures: Aut X X X X X X X X X	•	•			
C Virus (HCV) and Pharmaceutical Treatment Initiation For both PIPs, the MCO should devote adequate resources and staff to future PIPs to correctly calculate measures and assure the PIP's validity. Compliance with Adequate Capacity and Service O The MCO should improve access to PCPs for their urban members. O The MCO should assess the extent to which their instate network is sufficient to meet the needs of individuals with a dual diagnosis of behavioral health and developmental disabilities. Performance Measures Quality of Care Surveys – Member Nine (9) of 27 CAHPS measures fell below the 50th percentile; the MCO should continue to work to improve CAHPS scores that perform below the 50th percentile. The MCO should develop specific interventions to address the worst performing CAHPS measures: O Adult population:	~	•			
Pharmaceutical Treatment Initiation For both PIPs, the MCO should devote adequate resources and staff to future PIPs to correctly calculate measures and assure the PIP's validity. Compliance with Medicaid and CHIP Managed Care Regulations The MCO should improve access to PCPs for their urban members. The MCO should assess the extent to which their in- state network is sufficient to meet the needs of individuals with a dual diagnosis of behavioral health and developmental disabilities. Performance Measures Quality of Care Surveys – Member Nine (9) of 27 CAHPS measures fell below the 50th percentile; the MCO should continue to work to improve CAHPS scores that perform below the 50th percentile. The MCO should develop specific interventions to address the worst performing CAHPS measures: Adult population:	•		Х		X
Initiation For both PIPs, the MCO should devote adequate resources and staff to future PIPs to correctly calculate measures and assure the PIP's validity. Compliance with Medicaid and CHIP Managed Care Regulations The MCO should improve access to PCPs for their urban members. The MCO should assess the extent to which their instate network is sufficient to meet the needs of individuals with a dual diagnosis of behavioral health and developmental disabilities. Performance Measures Quality of Care Surveys – Member Nine (9) of 27 CAHPS measures fell below the 50th percentile; the MCO should continue to work to improve CAHPS scores that perform below the 50th percentile. The MCO should develop specific interventions to address the worst performing CAHPS measures: Adult population:	Pharmaceutical				
For both PIPs, the MCO should devote adequate resources and staff to future PIPs to correctly calculate measures and assure the PIP's validity. Compliance with Medicaid and CHIP Managed Care Regulations O The MCO should improve access to PCPs for their urban members. O The MCO should assess the extent to which their instate network is sufficient to meet the needs of individuals with a dual diagnosis of behavioral health and developmental disabilities. Performance Measures Quality of Care Surveys – Member Nine (9) of 27 CAHPS measures fell below the 50th percentile; the MCO should continue to work to improve CAHPS scores that perform below the 50th percentile. The MCO should develop specific interventions to address the worst performing CAHPS measures: O Adult population:	Treatment				
and staff to future PIPs to correctly calculate measures and assure the PIP's validity. Compliance with Medicaid and CHIP Managed Care Regulations O The MCO should improve access to PCPs for their urban members. O The MCO should assess the extent to which their instate network is sufficient to meet the needs of individuals with a dual diagnosis of behavioral health and developmental disabilities. Performance Measures Quality of Care Surveys – Member Nine (9) of 27 CAHPS measures fell below the 50th percentile; the MCO should continue to work to improve CAHPS scores that perform below the 50th percentile. The MCO should develop specific interventions to address the worst performing CAHPS measures: O Adult population:	Initiation				
and staff to future PIPs to correctly calculate measures and assure the PIP's validity. Compliance with Medicaid and CHIP Managed Care Regulations O The MCO should improve access to PCPs for their urban members. O The MCO should assess the extent to which their instate network is sufficient to meet the needs of individuals with a dual diagnosis of behavioral health and developmental disabilities. Performance Measures Quality of Care Surveys – Member Nine (9) of 27 CAHPS measures fell below the 50th percentile; the MCO should continue to work to improve CAHPS scores that perform below the 50th percentile. The MCO should develop specific interventions to address the worst performing CAHPS measures: O Adult population:		For both PIPs, the MCO should devote adequate resources			
assure the PIP's validity. Compliance with Medicaid and CHIP Medicaid and CHIP Managed Care Regulations The MCO should improve access to PCPs for their urban members. The MCO should assess the extent to which their instate network is sufficient to meet the needs of individuals with a dual diagnosis of behavioral health and developmental disabilities. Performance Measures Quality of Care Surveys – Member Nine (9) of 27 CAHPS measures fell below the 50th percentile; the MCO should continue to work to improve CAHPS scores that perform below the 50th percentile. The MCO should develop specific interventions to address the worst performing CAHPS measures: Adult population:		·			
Compliance with Medicaid and CHIP Medicaid and CHIP Managed Care Regulations The MCO should improve access to PCPs for their urban members. The MCO should assess the extent to which their instate network is sufficient to meet the needs of individuals with a dual diagnosis of behavioral health and developmental disabilities. Performance Measures Quality of Care Surveys – Member Nine (9) of 27 CAHPS measures fell below the 50th percentile; the MCO should continue to work to improve CAHPS scores that perform below the 50th percentile. The MCO should develop specific interventions to address the worst performing CAHPS measures: Adult population:		•			
Managed Care Regulations The MCO should assess the extent to which their instate network is sufficient to meet the needs of individuals with a dual diagnosis of behavioral health and developmental disabilities. Performance Measures Quality of Care Surveys – Member Nine (9) of 27 CAHPS measures fell below the 50th percentile; the MCO should continue to work to improve CAHPS scores that perform below the 50th percentile. The MCO should develop specific interventions to address the worst performing CAHPS measures: Adult population:	Compliance with				
Managed Care Regulations The MCO should assess the extent to which their instate network is sufficient to meet the needs of individuals with a dual diagnosis of behavioral health and developmental disabilities. Performance Measures Quality of Care Surveys – Member Nine (9) of 27 CAHPS measures fell below the 50th percentile; the MCO should continue to work to improve CAHPS scores that perform below the 50th percentile. The MCO should develop specific interventions to address the worst performing CAHPS measures: Adult population:	Medicaid and CHIP				
Regulations The MCO should assess the extent to which their instate network is sufficient to meet the needs of individuals with a dual diagnosis of behavioral health and developmental disabilities. Performance Measures Quality of Care Surveys – Member Nine (9) of 27 CAHPS measures fell below the 50th percentile; the MCO should continue to work to improve CAHPS scores that perform below the 50th percentile. The MCO should develop specific interventions to address the worst performing CAHPS measures: Adult population:	Managed Care	urban members.			
state network is sufficient to meet the needs of individuals with a dual diagnosis of behavioral health and developmental disabilities. Performance Measures Quality of Care Surveys – Member Nine (9) of 27 CAHPS measures fell below the 50th percentile; the MCO should continue to work to improve CAHPS scores that perform below the 50th percentile. • The MCO should develop specific interventions to address the worst performing CAHPS measures: • Adult population:	-	 The MCO should assess the extent to which their in- 	Х		X
and developmental disabilities. Performance Measures Quality of Care Surveys – Member Nine (9) of 27 CAHPS measures fell below the 50th percentile; the MCO should continue to work to improve CAHPS scores that perform below the 50th percentile. The MCO should develop specific interventions to address the worst performing CAHPS measures: Adult population:		state network is sufficient to meet the needs of			
Performance Measures Quality of Care Surveys – Member Nine (9) of 27 CAHPS measures fell below the 50th percentile; the MCO should continue to work to improve CAHPS scores that perform below the 50th percentile. The MCO should develop specific interventions to address the worst performing CAHPS measures: Adult population:		individuals with a dual diagnosis of behavioral health			
Measures Quality of Care Surveys – Member Nine (9) of 27 CAHPS measures fell below the 50th percentile; the MCO should continue to work to improve CAHPS scores that perform below the 50th percentile. • The MCO should develop specific interventions to address the worst performing CAHPS measures: • Adult population:		and developmental disabilities.			
Quality of Care Surveys – Member Nine (9) of 27 CAHPS measures fell below the 50th percentile; the MCO should continue to work to improve CAHPS scores that perform below the 50th percentile. • The MCO should develop specific interventions to address the worst performing CAHPS measures: • Adult population:	Performance	None identified.			
Surveys – Member the MCO should continue to work to improve CAHPS scores that perform below the 50th percentile. • The MCO should develop specific interventions to address the worst performing CAHPS measures: • Adult population:	Measures				
that perform below the 50th percentile. • The MCO should develop specific interventions to address the worst performing CAHPS measures: • Adult population:	Quality of Care	Nine (9) of 27 CAHPS measures fell below the 50th percentile;			
 The MCO should develop specific interventions to address the worst performing CAHPS measures: Adult population: 	Surveys – Member	the MCO should continue to work to improve CAHPS scores			
address the worst performing CAHPS measures: O Adult population:		that perform below the 50th percentile.			
o Adult population:		• The MCO should develop specific interventions to			
		address the worst performing CAHPS measures:			
The second of th		 Adult population: 		v	v
• Getting Care Quickly (< 25th percentile)		 Getting Care Quickly (< 25th percentile) 	X	X	Х
■ How Well Doctors Communicate (< 25th					
percentile)		·			
o Child General population:		 Child General population: 			
■ How Well Doctors Communicate (< 25th		 How Well Doctors Communicate (< 25th 			
percentile)		percentile)			
Network None identified.	Network	None identified.			
Adequacy	Adequacy				
Quality Ratings None identified	Quality Ratings	None identified.			

¹The final interim rates reported extend past the ATR review period (July 1 2019 – June 30 2020). This allowed for sufficient data to be reported to draw conclusions about the PIP.

EQR: external quality review; ACLA: AmeriHealth Caritas Louisiana; PIP: performance improvement project; MCO: managed care organization; AOD: Alcohol and Other Drug; HEDIS: Healthcare Effectiveness Data and Information Set; NCQA: National Committee for Quality Assurance; LOBs: lines of business; PPOs: preferred provider organization; CAHPS: Consumer Assessment of Healthcare Providers and Systems; MY: measurement year; ITM: intervention treatment measure; SUD: substance use disorder; PCP: primary care provider.

XI. Appendix A

MCO Verbatim Responses to IPRO's Health Disparities Questionnaire

For this year's technical report, the LA EQRO evaluated MCOs with respect to their activities to identify and/or address gaps in health outcomes and/or health care among their Medicaid population according to at-risk characteristics such as race, ethnicity, gender, and geography. MCOs were asked to respond to the following questions for the period July 1, 2020–June 30, 2021:

Did the MCO conduct any studies, initiatives, or interventions to identify and/or reduce differences in health outcomes, health status, or quality of care between the MCO's Medicaid population and other types of health care consumers (e.g., commercial members) or between members in Medicaid subgroups (e.g., race, ethnicity, gender, age, socio-economic status, geography, education)?

[Response and formatting below were taken directly from the MCO submissions]

ACLA Response

<u>Health Equity, Louisiana Style – Health Equity Workgroup</u>

AmeriHealth Caritas Louisiana reviews member responses from the Consumer Assessment of Healthcare Providers and Systems (CAHPS) survey and Healthcare Effectiveness Data and Information Set (HEDIS) outcomes to identify opportunities for improvement among groups. CAHPS and HEDIS* results are stratified by geography (urban/rural), race, ethnicity and language (REL) for comparison. Datasets for each REL and location group are reviewed and compared annually to identify disparities and trending performance. Our *Health Equity, Louisiana Style* cross-departmental workgroup develops programs and initiatives to improve health outcomes and address identified disparities between compared groups using a root cause approach. The workgroup developed two specific initiatives during this period to address disparate outcomes for Black members living in rural areas and Hispanic/Spanish-speaking members across the state. In addition, the workgroup developed a targeted provider engagement strategy aimed at these improvements.

Provider Engagement/Education

- Targeted rural provider outreach/education regarding area disparities and what they can do to improve outcomes.
- Provider Advisory Council discussions on health equity, implicit and explicit bias and how the Plan can strengthen its provider relationships to improve member care compliance and satisfaction.
- Account Executive talking points used in spoken and written communications.
- Ongoing reminders of Plan health equity activity and goals through Provider Post.
- Engagement and education of community health centers on area language needs, free language services and service area demographics.

Hispanic/Spanish-speaking members

El Conocimiento es Poder (Knowledge is Power) - Statewide Education/Engagement Push

Improve outcomes in PPC (Timeliness of Prenatal Care)/PPC (Postpartum Care) and CAHPS responses by addressing the knowledge gap of Plan offerings for Hispanic and Spanish-speaking members through culturally and linguistically cohesive statewide member outreach and orchestrated provider education push. Intervention components include the following:

- Prioritization of target parishes based on identified Hispanic and Spanish-speaking members, HEDIS outcomes, and presence of Spanish-speaking providers.
- Targeted member education that addresses language services, maternal support programs and services, medical transportation, case management, GED program support and housing services.
- Development of Standard Operating Procedures for engaging members in this REL group in in-person activities and events.
- Collaboration with Hispanic and Spanish-speaking organizations to facilitate patient advocacy.

<u>Timeliness of Prenatal Care member outreach (pilot) project</u> – Outreach project focused on identifying barriers/interventions to support the Timeliness of Prenatal Care measure. The goal was to identify why identified pregnant members did not receive care in a timely manner based on the HEDIS Specs. A pilot group of women was identified and scripting/questions regarding their first OB appointment were completed via outreach calls to identify any barriers to receiving prenatal care in a timely manner. Results from this outreach project were reviewed and discussed at the Maternity QIA Workgroup and the group is currently reviewing/discussing disparity opportunities and interventions.

<u>Bilingual Baby Showers</u> – Showers targeted our member population whose preferred language is Spanish. The entire shower was presented in Spanish to ensure the audience was receiving information in a way that was specific to their needs from trustworthy sources. Bright Start and ACLA services and member benefits for pregnant and new moms along with the United Way, Governor's Office for Homeland Security, Early Steps, Nurse Family Partnership, and WIC were presented, along with a healthy-recipe cooking demo. Topics included: How to stay safe during hurricane season; accessing United Way Services; Nurse Family Partnership Services and how to apply; What is WIC and how to apply; Healthy Recipes: *Hash de Camote*; Safe Sleep; Keys to Your Care; Importance of Full-term Birth; Gestational Diabetes; Breast Feeding; and Care Card Incentives.

Black members

Comprehensive Diabetes Care

Improve health outcomes in Comprehensive Diabetes Care for Black members living in rural areas through proactive member education that directly addresses Plan services that help members overcome known barriers to care. Intervention components include the following:

- Geographically targeted parishes classified as rural by Louisiana Department of Health.
- Diabetic education collateral (print and electronic) that include information on transportation, healthy eating, getting an earlier appointment, behavioral health support, finding an eye doctor, and more.
- Recommended enhanced pharmacy website search options to make geographic searches more effective, including display options for those pharmacies that offer delivery services.
- Member bias survey (via text messaging).
- Member Advisory Council meetings focused on rural parishes.

Maternal Care

Sista Midwife Collaboration (C-section Outreach) – Based on feedback from the community about the need to provide a safe place for moms-to-be to access education and resources, we collaborated with Sista Midwife Productions (SMP) through our New Orleans Wellness & Opportunity Center, where we hosted SMP's Birth Story Project, which provided a safe space for Black women to speak about their birth experiences.

Children and Families

Well-Child Visits in the First 15 Months of Life (W15)/Childhood Immunization Status (CIS) Mailer – Monthly mailer to Black children 4 months old who have had 3 or less well visits.

Childhood Immunization Status Member Outreach Calls – Member outreach calls made during 2021 to various members in Louisiana, ages birth to two years, who had not yet received vaccines for HEDIS measure Childhood Immunization Status (Combos 3, 10). Some regional targeted outreach calls were made to address a disparity of high non-compliance rates.

XII. Appendix B

IPRO's Assessment of the Louisiana Medicaid Quality Strategy

Evaluation Methodology

To evaluate Louisiana's 2019 Medicaid Managed Care Quality Strategy, a review of federal regulations was initially conducted to clearly define the requirements of the Quality Strategy and guide the evaluation methodology.

First, IPRO evaluated the core Healthy Louisiana performance results. This evaluation consisted of data analysis of measures identified in the Quality Strategy from the HEDIS, CAHPS, AHRQ's Preventive Quality Indicators, Louisiana vital records, and CMS-developed measures. This analysis included comparisons of Louisiana HEDIS performance to national benchmarks using the Medicaid NCQA *Quality Compass*[®].

Second, IPRO evaluated Louisiana Medicaid's Quality Monitoring activities. This evaluation consisted of a review of Louisiana Department of Health monitoring reports regarding enrollment, network adequacy, quality dashboard, program transparency, medical loss ratio (MLR) and diabetes and obesity reviews. LDH's approach to addressing health disparities and the use of sanctions were also reviewed. Further evaluation of the Quality Strategy consisted of a review of external quality review (EQR) report documents, including performance measure results, compliance review results, access and availability survey findings, behavioral health member satisfaction, and the Annual EQR Technical Reports.

Third, IPRO evaluated State-MCO-EQRO communications by reviewing online data sources. In addition to the LDH and external quality review monitoring reports, other website examples of data transparency such as MCO executed contracts, Medical Care Advisory Committee meeting reports and Informational Bulletins were reviewed.

Fourth, IPRO evaluated Louisiana Medicaid's strategies and interventions to promote quality improvement by reviewing MCO Performance Improvement Project reports, MCO withhold of capitation payments to increase the use of Value-Based Payment and improve health outcomes, and the Louisiana Health Information Technology Roadmap.

Finally, based on key findings, IPRO prepared a summative analysis of program strengths, opportunities for improvement, and recommendations.